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Recent evidence suggests that sustained consumption of a high-fat diet is 
associated with reduced CB1 receptor expression in some brain areas. Many of the 
neuromodulatory functions of endogenous cannabinoids are mediated by the CB1 
receptor. The CB1 receptor also mediates the behavioral and physiological effects of 9-
tetrahydrocannabinol (9-THC), the primary psychoactive constituent of marijuana. 
While high-fat diets are associated with region-specific changes in CB1 receptor 
expression, it is not clear whether such changes are behaviorally relevant. To that end, 
separate groups of male and female rats were placed on either a high-fat diet or a standard 
xdiet. Cannabinoid function was determined in a triad of measures (e.g., hypothermia, 
gross locomotion, time on bar apparatus) at postnatal day 30 (PD30), PD44, PD68 and 
PD114. These age points respectively correspond to rodent models of early adolescence, 
late adolescence, early adulthood and full maturity in humans. Male rats were also tested 
at PD37 and PD61. Subsequently, the antinociceptive properties of 9-THC and the effect 
of 9-THC on food intake were also measured. After 38 days, female rats maintained on 
a high-fat diet were significantly less sensitive to the psychomotor effects of 9-THC 
than were the female rats maintained on the control diet. These diet-related differences 
persisted into full maturity. Female rats maintained on a high-fat diet were also less 
sensitive to changes in food intake caused by 9-THC than were female rats maintained 
on the control diet. In contrast, the hypothermic effects of 9-THC were not differentially 
affected by the type of diet consumed. Likewise, female rats maintained on a high-fat diet 
exhibited tail-flick latencies that were indistinguishable from those of female rats 
maintained on the control diet. With two minor exceptions, and in sharp contrast to 
female rats, sensitivity to the pharmacological effects of 9-THC was not differentially 
affected by the type of diet in male rats. In short, female rats maintained on a high-fat diet 
appeared to be cross-tolerant to the psychomotor and hyperphagic effects of 9-THC 
while male rats maintained on a high-fat diet exhibited responses to 9-THC that were 
virtually indistinguishable from control animals.
1Introduction
The Endogenous Cannabinoid System
The endogenous cannabinoid, or endocannabinoid, system is a lipid-based 
signaling system that is composed of two known ligands, several putative ligands, at least 
two types of G-protein-coupled receptors, a pair of hydrolytic enzymes, and may also 
include a dedicated reuptake transporter. Endocannabinoids act at the CB1 receptor to 
modulate neural impulses in the central nervous system, to modulate activity in the 
reproductive system and the gastrointestinal and also play an important role in regulating 
lipogenesis (Di Marzo et al., 1998; Cota et al., 2003). The CB2 receptor is found 
primarily in immune cells (Munro et al., 1993;  Galiegue et al., 1995) where it modulates 
immune function (Schatz et al., 1997; Cabral, 2001). Recent reports suggest that CB2
receptors are also detectable in neurons (Brusco et al., 2008), but these data remain 
controversial and the function of these receptors, if present, is unclear.
Endocannabinoids are most commonly synthesized in the postsynaptic density of 
GABAergic and glutamatergic neurons (Rodriguez de Fonseca et al., 2005).  Once 
synthesized, endocannabinoids can traverse backward across the synaptic cleft to inhibit 
presynaptic neural impulses (Wilson and Nicoll, 2001).  Endocannabinoids may attenuate 
inhibitory signals in some brain areas by limiting the release of the inhibitory 
neurotransmitter gamma-aminobutyric acid (GABA; Maneuf et al, 1996; Wilson et al., 
2001) through a process known as depolarization-induced suppression of inhibition (DSI; 
2Pitler and Alger, 1994; Kreitzer and Regehr, 2001A). During DSI, endocannabinoids act 
to reduce calcium-ion uptake at the axon terminals of the presynaptic neuron, which 
suppresses the binding of vesicles to the cell membrane and the subsequent release of 
GABA into the synapse.  Similarly, endocannabinoids may produce depolarization-
induced suppression of excitation (DSE) by inhibiting the release of the excitatory 
neurotransmitter glutamate (Kreitzer and Regehr, 2001B). Endocannabinoids also appear 
to inhibit the action of dopaminergic (Giuffrida et al, 1999) and serotoninergic neurons 
(Best and Regehr, 2008).  In keeping with their neuromodulatory role, endocannabinoids 
are only synthesized when and where they are needed. The interval during which 
endocannabinoids exert their physiological influence is brief because they are degraded 
rapidly.
Though CB1 receptors are distributed widely throughout the brain, they are 
densely packed in the cerebral cortex, striatum, globus pallidus, substantia nigra, nucleus 
accumbens, hippocampus, and the cerebellum (Herkenham et al., 1990; Bliss and 
Collingridge, 1993; Collins et al., 1994; Miller and Walker, 1995; Herkenham et al., 
1991; Herkenham et al., 1990; Rodriguez de Fonseca; 1998).  The list of functions 
associated with these brain areas (e.g., cognition, locomotor function, learning and 
memory, reward, coordination and balance) highlight the physiological significance of 
the endocannabinoid system.  Endocannabinoids are also known to play an important role 
in energy balance and metabolism. Although CB1 receptor densities are relatively low in 
the hypothalamus (Fitton and Pertwee, 1982; Mattes et al., 1994), activation of the G-
3proteins that are coupled to CB1 receptors in the hypothalamus is highly efficient 
(Breivogel et al., 1997).
Elucidation of the endocannabinoid system began in earnest with the isolation of 
(-)9-tetrahydrocannabinol (9-THC), the primary psychoactive constituent of Cannabis 
sativa (Gaoni and Mechoulam, 1964).  For two decades, researchers worked to 
understand the behavioral pharmacology of cannabinoids, all while lacking a well-
understood mechanism of action. Some thought that cannabinoids, which are highly 
lipophilic, could exert their affects by passive diffusion into neurons or by altering the 
fluidity of the cell membrane (Leuschner et al., 1986).
The array of physiological effects produced by cannabinoids and the observation 
that at least some cannabinoids displayed high-affinity for a binding site in the brain, 
however, led many to believe that cannabinoid pharmacology must be receptor-mediated 
(Harris et al., 1978; Nye et al., 1985; Mechoulam, 2006). For instance, the (-)isomer of 
the cannabinoid agonist 11-hydroxy-delta 8-tetrahydrocannabinol-dimethylheptyl 
(HU210) is at least several hundred times more potent than the (+)-isomer (HU211; Little 
et al., 1989). This disparity in potency between optical isomers is indicative of 
stereospecific binding at a receptor (Soudjin, et al., 2003).  
Shortly after cannabinoid receptors were discovered in the brain, (Devane et al., 
1988), the receptor itself was cloned (Matsuda et al., 1990). Initially identified as SKR6, 
the newly cloned receptor interacted cannabinoid ligands (i.e., 9-THC, CP55, 940) but
failed to interact with other ligands (i.e., bradykinin, angiotensin II, cholecystokinin) in 
radioligand binding assays. This newly discovered receptor also produced dose-
4dependent changes in forskolin-stimulated accumulation of cAMP when stimulated with 
9-THC and CP55, 940. These drug-induced changes in cAMP concentration occurred in 
a stereoselective manner; the (+)isomers of 9-THC and CP55, 940 were much less 
potent than the (-)isomers. Importantly, SKR6 was found to be distributed in the same 
brain regions as the previously identified cannabinoid receptor.
Cannabinoid receptors belong to a class of receptors called G-protein-coupled 
receptors (GPCRs). GCPRs are metabotropic receptors and, as such, exert their 
physiological influence through a series of second-messengers (i.e., cAMP, PIP3; 
Rodbell, 1997). These receptors and their downstream effectors regulate a complex series 
of downstream reactions in a process collectively referred to as “signal transduction” 
(Rodbell, 1995).  
In an inactive state, the G-protein complex consists of a receptor with 7-
transmembrane domains, a complex of 3-subunits (, , and ) that is bound to the 
cytosolic face of the cell membrane and a molecule of guanosine diphosphate (GDP; 
Rodbell, 1995; Rodbell, 1997). When a ligand binds to the receptor, the complex is 
activated and undergoes a conformational change that decreases the affinity of the G
subunit for GDP and increases the affinity of the G subunit for GTP. When GTP binds 
to the G subunit, another conformational change reduces the affinity of the G subunit 
for the G subunits.  The G-GTP complex then dissociates from the rest of the GPCR 
complex. Once dissociated, the G-GTP complex activates the appropriate second 
messenger. In the process of activating the second messenger, the G-GTP complex is 
5dephosphorylated to form a G-GDP complex. Once bound to GDP, the G subunit 
again joins the G subunits and the GPCR returns to an inactive state.
The newly cloned CB1 receptor was useful in the effort to isolate an endogenous 
cannabinoid ligand. The first known endocannabinoid was identified from porcine tissue 
samples (Devane et al., 1992) and became known as “anandamide”. Anandamide is a 
contraction of the Sanskrit word for “bliss” (ananda) and the term for the central chemical 
moiety of the associated structure (an amide). Anandamide is a derivative of arachidonic 
acid and is formally known as N-arachidonyl ethanolamine (AEA). The phospholipid 
precursor to anandamide, N-phosphatidyl ethanolamine (NAPE), is produced when an 
enzyme known as N-acyltransferase transfers an arachidonic acid molecule to a molecule 
of phosphatidylcholine (Cadas et al., 1996; Piomelli, 2003). The production of NAPE is 
calcium-dependent and is regulated by cAMP. The enzymes that cleave anandamide from 
NAPE include N-phosphatidyl ethanolamine phospholipase D (NAPE-PLD), but other 
phospholipase enzymes likely play a role in anandamide synthesis (Leung et al., 2006).
Anandamide is an agonist at CB1 receptors (Mechoulam and Fride, 1993) and has 
a pharmacological profile similar to that of 9-THC (Crawley et al., 1993; Weidenfeld et 
al., 1994; Williams and Kirkham, 1999). The CB1 receptor is typically coupled to Gi/Go 
proteins. As such, CB1 receptor stimulation by an agonist like anandamide inhibits the 
formation of cAMP and, consequently, reduces the activity of phosphokinase A (PKA).  
The downstream effects of reduced PKA activity include diminished phosphorylation of 
a variety of target enzymes. Recent evidence suggests that the highly lipophilic nature of 
endocannabinoids allows them to bind to and activate cannabinoid receptors from within 
6the lipid bilayer unlike hydrophilic ligands that must bind while being stabilized in the 
polar extracellular space (Nebane et al., 2008).
Several years after the identification of anandamide, a second endocannabinoid, 
2-arachidonoylglycerol (2-AG), was identified (Mechoulam et al., 1995).  While 
anandamide is now thought of as a partial agonist at the CB1 receptor, 2-AG is generally 
regarded as a full-agonist and is found in much higher concentrations in the brain than 
anandamide (Gonsiorek et al., 2000; Sugiura et al., 1995; Stella et al., 1997). Despite the 
similarity of the pharmacological profile of anandamide and 2-AG, they are produced 
through discrete synthetic pathways.
The pathways that produce 2-AG are robust because of the variety and 
redundancy of the precursors and enzymes that can be employed. The primary precursors 
of 2-AG are phosphatidylinositol bisphosphate (PIP2), phosphatidylinositol (PI) or 
phosphatidylcholine (PC), all of which are phospholipids that are commonly found in the 
cell membrane (Sugiura et al., 2006).  These precursors can be converted to 2-AG by the 
coordinated action of phospholipase A1, phospholipase C and/or diacylglycerol lipase 
(Sugiura et al., 1995). In an alternate pathway, phosphatase enzymes can convert the 
conjugate of arachidonic acid and lysophosphatidic acid (2-arachidonyl LPA) into 2-AG 
(Nakane et al., 2002). 
Early on, it became apparent that the duration of action of endocannabinoids is 
limited because the compounds are rapidly hydrolyzed (Deutsch and Chin, 1993).  The 
primary enzyme that degrades anandamide is called fatty-acid amidohydrolase (FAAH; 
Cravatt et al., 1996). FAAH, which belongs to a class of enzymes called serine 
7hydrolases, is promiscuous and can hydrolyze whole classes of long-chain 
acylethanolamines and primary amides. FAAH is primarily found on the membranes of 
cytoplasmic organelles (i.e., mitochondria, smooth endoplasmic reticulum) and the 
intracellular face of the plasma membrane in postsynaptic neurons (Gulyas et al., 2004). 
It has been hypothesized that FAAH held the capacity to degrade 2-AG as well as 
anandamide, but recent work suggests that FAAH is not an important contributor to 2-AG 
hydrolysis in the brain (Blankman et al., 2007).  
The enzyme that is primarily responsible for 2-AG hydrolysis is called 
monoacylglycerol lipase (MAGL; Dinh et al., 2002). MAGL has more substrate 
specificity that FAAH and can only hydrolyze a subset of monoacylglycerols (Matias et 
al., 2006). MAGL also seems to function presynaptically (Gulyas et al., 2004), while 
FAAH seems to function as a postsynaptic enzyme. Because the pathways that produce 
endocannabinoids are not under unified control and because the enzymes that degrade 
endocannabinoids are found in distinct subcellular regions, some have suggested that 
anandamide and 2-AG play unique roles in the endocannabinoid system (Chevaleyre et 
al., 2003).
Pharmacological Effects of Cannabinoids
A cluster of four tests conducted in mice, commonly referred to as the “Martin 
Tetrad”, are used to probe for the signature effects of cannabinoid drugs.  The tetrad 
includes measures of transient hypothermia, antinociception, locomotor inhibition and 
catalepsy-like behavior (Loewe, 1946; Hardman et al., 1971; Smith et al., 1994; 
Chaperon and Theibot, 1999).
8In rodents, both anandamide and 9-THC can reduce rectal temperature by in 
excess of 5oC (Smith et al., 1994; Hosko et al., 1981). Other drugs with cannabinoid 
activity (i.e., CP55,940, WIN 55212-2) have also been reported to produce similar 
hypothermic responses (Compton et al., 1992; Rawls et al., 2007). The amount 
cannabinoid-induced hypothermia is dose-dependent and is affected by the route of 
administration.  Recent evidence suggests that inhibitors of endocannabinoid hydrolysis 
can also reduce body temperature significantly (Burston et al., 2008; Long et al., 2009).
The mechanism by which cannabinoids reduce body temperature is unclear, but 
the amount and duration of hypothermia may be regulated in the anterior hypothalamus 
and the caudal portion of the brainstem (Schmeling and Hosko, 1976; Hosko et al., 
1981). While cannabinoids induce hypothermia, this transient reduction in body 
temperatures may involve receptors other than CB1. For example, AM404, a drug that 
elevates endocannabinoid levels in the synapse, produces a hypothermic response in mice 
that can be blocked by a vanilloid (TRPV1) receptor antagonists (Rawls et al., 2006). 
Similarly, hypothermia produced by cannabinoid agonists can be attenuated by 
nociceptin/orphanin FQ (N/OFQ) receptor antagonists (Rawls, et al., 2007).
Cannabinoids also produce catalepsy-like behavior in mice and rats (Grunfeld and 
Edery, 1969). Catalepsy is characterized by muscle rigidity and the maintenance of a 
fixed posture, even if the posture might appear to be uncomfortable (Sanberg et al., 
1988). Catalepsy induced by 9-THC may involve diminished 5-HT(2A) and 5-HT(1A) 
signaling in the nucleus accumbens (Sano et al., 2008; Egashira et al., 2007; Egashira et 
9al., 2006). This reduction in serotonergic signaling is likely related to the inhibitory 
activity of 9-THC at glutamatergic neurons. 
In addition to inducing catalepsy-like behavior, cannabinoids also inhibit 
locomotion at moderate and high doses.  Varying degrees of immobility are observed 
after treatment with a variety of cannabinoids (i.e., anandamide, 9-THC; Rodreiguez de 
Fonseca et al., 1998). Evidence derived from experiments with non-human primates 
suggests that cannabinoid-induced locomotor inhibition may be related to decreased 
dopaminergic signaling at dopamine D2 neurons (Meschler et al., 2000). In these studies, 
locomotor activity was significantly inhibited when a sub-threshold dose of the CB1
agonist levontradol was combined with sub-threshold doses of quinelorane or pergolide, 
both of which are dopamine D2 agonists. The dopamine D1 agonist SKF81297, however, 
did not alter the relationship between levontradol and locomotor activity.
Evidence from rats corroborate the putative relationship between dopamine D2
receptors, cannabinoids and locomotor activity (Marcelllino et al., 2008). The 
cannabinoid agonist CP55, 940 dose-dependently reduced the affinity of dopamine D2
receptor binding sites in membrane preparations derived from the dorsal and ventral 
striatum of rat brains. Sub-threshold doses of CP55, 940 attenuated the locomotor 
stimulation produced by quinpirole, a dopamine D2 agonist, in these same studies.
Cannabinoids are thought to produce antinociception by synergistically 
interacting with opioid receptors and 2-adrenoreceptors (Cichewicz and McCarthy, 
2003; Tham et al., 2005; Cox et al., 2007). Evidence from mice suggests that 
cannabinoid receptors and kappa opioid receptors are co-localized in the dorsal horn of 
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the spinal cord and interact to modulate the transmission of noxious stimuli from sensory 
neurons (Smith et al., 1994; Reche et al., 1996). Blockade of CB1 receptors by AM281 
has been shown to produce a compensatory elevation of kappa opioid receptors in the 
spinal cord of mice (Saez-Cassanelli et al., 2007). In those same experiments, AM281-
induced antinociception was reversed by nor-binaltorphimine, a kappa opiod antagonist. 
Additionally, cannabinoid receptors are thought to interact with mu opioid receptors in 
the brain are thought to reduce the perception of noxious stimuli (Reche et al., 1996). In 
tail-flick and hot plate tests with mice, sub-threshold doses of morphine augmented the 
antinociceptive properties of 9-THC in a synergistic fashion. This effect was blocked by 
the mu-opiod receptor antagonist -funaltrexamine as well as a kappa-opioid receptor 
antagonist and a CB1 receptor antagonist. 
Animal Models of Adolescence and the Development of the Endocannabinoid System
Adolescence and puberty are temporally-related events, though each has a distinct 
definition.  Puberty refers to the attainment of sexual maturity (Graber and Brooks-Gunn, 
1998) while adolescence is the gradual period of transition from childhood to adulthood 
(Pickles et al., 1998).  Because the onset of adolescence cannot be defined by any single 
biochemical, endocrine or neuroanatomical milestone, it is difficult to characterize the 
precise timing and duration of adolescence in physiological terms (Rosenblum, 1990).  
Instead, adolescence can be characterized by age-specific behaviors such as 
increased risk-taking and social interaction.  The behavior of adolescent animals is also 
highly peer-directed and is characterized by novelty-seeking.  In rats, adolescent-typical 
11
behavior is commonly observed between postnatal day 28 and postnatal day 42 (Spear, 
2000).
The behavioral changes associated with adolescence do not seem to be 
significantly related to changes in gonadal hormonal levels (Brooks-Gunn et al., 1994).  
Instead the maturational changes in the brain that occur around postnatal day 28-42 
contribute to the age-specific behavioral characteristics of adolescence (Spear, 2000).  
During adolescence many brain regions (i.e., prefontal cortex) and brain systems (i.e., 
dopaminergic system) are undergoing important changes (Van Eden et al., 1990).  
Another system undergoing such change is the endocannabinoid system.
Endocannabinoids play an important role in neurological development 
(Fernandez-Ruiz et al., 1999) and, in rodents, the endogenous cannabinoid system 
continues to mature well after birth (Rodriguez de Fonseca et al., 1993; Belue et al., 
1995).  There are subtle sex-differences in the timing of CB1 receptor development, but 
both sexes express maximum CB1 receptor densities between postnatal day 30 and 
postnatal day 40. As adolescence draws to a close (postnatal day 40), male rats express 
greater CB1 receptor density in the midbrain than females and that trend continues into 
early adulthood, although CB1 receptor density is similar in other brain areas (Rodriguez 
de Fonseca et al., 1993).  By adulthood (postnatal day 90), CB1 receptor densities 
stabilize in all brain areas (Belue et al., 1995). Some data suggest CB1 receptor density 
declines in a region specific manner (e.g., cerebellum, hypothalamus, hippocampus; 
Berrendero et al., 1998) as rats age beyond two years, but there is also evidence that 
whole brain receptor densities do not change significantly up to thirty-two months of age 
12
(Belue et al., 1995).  While the CB1 receptor densities change during maturation, receptor 
affinity does not appear differ dramatically during development (McLaughlin et al., 
1994). 
While CB1 receptors mature slowly during the postnatal period, behavioral data 
suggest that the endocannabinoid system reaches functional maturity during adolescence. 
There is some evidence that very young rodents (postnatal day 6 though postnatal day 23) 
exhibit little locomotor inhibition or antinociception after treatment with anandamide or 
9-THC (Fride and Mechoulam, 1996A; Fride and Mechoulam, 1996B). This is relevant 
because changes in locomotion and antinociception, along with hypothermia and 
catalepsy-like behavior, are hallmarks of cannabinoid pharmacology (Smith et al., 1994). 
By the onset of adolescence (postnatal day 28), however, this pattern of response changes 
(Schramm-Sapyta et al., 2007; Wiley et al., 2008). In adult rodents, low doses of 9 -
THC can stimulate locomotion (Wiley et al., 2008), while larger doses of cannabinoid 
agonists typically inhibit locomotion and induce antinociception (Fride and Mechoulam, 
1996B). It is not yet clear, however, whether these age-related differences in cannabinoid 
pharmacology are linked to changes in CB1 receptor expression or sensitivity, cell 
signaling, cannabinoid pharmacokinetics or some other mechanism. 
Perhaps related to the slow maturation of the endocannabinoid system, there 
seems to be a vulnerable developmental period in rodents during which cannabinoid 
exposure produces long-lasting behavioral alterations, especially in behavior involving 
cognitive tasks (Stiglick and Kalant, 1985).  Other work in rodents shows that chronic 
pubertal treatment with cannabinoids produces long-lasting reductions in the motivation 
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to work for a food reward, but similar treatment during adulthood does not produce the 
same effect (Schneider and Koch, 2003).  There is complementary evidence from humans 
that long-lasting attentional deficits may be related to cannabis abuse that began before 
age sixteen (Ehrenreich et al., 1999).
Sex Differences in Cannabinoid Effects
There is evidence that males and females metabolize Δ9-THC differently.  
Experiments with liver cultures suggest that female rats overwhelmingly metabolize Δ9-
THC to 11-hydroxy-9-THC (Narimatsu et al., 1991), a potent psychoactive compound 
(Lemberger et al., 1973). In contrast, male rats metabolize Δ9-THC to a variety of 
compounds (including 11-hydroxy-9-THC).  This is significant because many of the 
other metabolites of Δ9-THC produced in male rats are less psychoactive than 11-
hydroxy-9-THC.  These observed ex vivo differences in the metabolism of Δ9-THC are 
corroborated by the observation that female rats have higher peak brain levels of 11-
hydroxy-9-THC than do male rats after intraperitoneal administration of Δ9-THC (Tseng 
et al., 2004). Importantly, blocking the metabolism of 9-THC eliminates sex-differences 
in antinociception in rats.
Human females have been shown to achieve higher maximal blood concentrations 
of 9-THC and do so more rapidly than males after oral consumption of cannabis 
(Nadulski et al., 2005). However, 9-THC can accumulate in fatty tissues (Nahas et al., 
1981), so it is possible that sex-related differences in body composition play a role in the 
bioavailability of 9-THC. In contrast, other studies with humans indicate few differences 
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in the degree to which men and women metabolize Δ9-THC to 11-hydroxy-9-THC, 
regardless of whether the drug was delivered intravenously or by mouth (Wall et al., 
1983). 
While sex-related differences in cannabinoid pharmacokinetics have been 
documented, there are also important sex-related differences in cannabinoid 
pharmacodynamic. For example, there may be sex-related differences in the degree to 
which cannabinoids alter neuronal signaling in the arcuate nucleus, a brain area that 
controls homeostatic function like food intake.  There is some evidence that rapidly-
inactivating, voltage-gated potassium channels (A-type K+ channels) in the 
hypothalamus are inhibited by cannabinoids to a greater degree in female guinea pigs 
than in male guinea pigs (Tang et al., 2005). The CB1 receptor agonists WIN55,212 and 
ACEA induced a rightward shift in the inactivation curve for these currents in females, 
but not in males. A rightward shift in this curve suggest that when treated with 
WIN55,212 or ACEA, more voltage-gated potassium channels are inhibited in females 
than in males. Consequently, a greater number of neuronal impulses are inhibited. The 
inhibitory effect of cannabinoids on these potassium channels were reversed after the 
application of a CB1 antagonist.
There are also important sex-related behavioral differences in cannabinoid 
pharmacology. When these sex differences are detected, females tend to be more 
sensitive to the pharmacological effects of cannabinoids than males (Cohn et al., 1972). 
In an experiment with humans, females treated with Δ9-THC exhibited a greater drop in 
cerebral blood velocity and blood pressure after standing (orthostatic hypotension) and 
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reported being more dizzy than males, even though the plasma levels of Δ9-THC were 
indistinguishable (Mathew et al., 2003). Cannabinoids may also induce antinociception 
and inhibit locomotion at lower doses in female rats than male rats (Tseng and Craft, 
2001).
It is also interesting to note that chronic exposure to Δ9-THC during adolescence 
exaggerates the relationship between nutritional status and motivation to work for a food 
reward as indexed by progressive-ratio breakpoints (Wright and Wiley, unpublished 
data). Unlike males, female rats continued to exhibit elevated progressive-ratio 
breakpoints even when they were tested at 100% of their pre-testing bodyweight. This 
observation suggests that the food reward used in these experiments may be a more 
efficacious reinforcer in female rats than in male rats 
High-Fat Diets and the Endogenous Cannabinoid System
The endocannabinoid system is a lipid-based signaling system and 
endocannabinoid levels appear to be influenced by the lipid content of the diet.  More 
specifically, the type and quantity of polyunsaturated fatty acids (PUFAs) found in the 
diet can directly influence the levels of endocannabinoid ligands in the body (Berger et 
al., 2001; Watanabe et al., 2003).  When mice and piglets are fed diets enriched with 
omega-6 polyunsaturated fatty acids, brain levels of anandamide and 2-AG increase 
significantly.  High levels of omega-6 polyunsaturated fatty acids are commonly found in 
corn oil, soybean oil and canola oil (Rodriguez-Cruz et al., 2005).  
Diets rich in omega-6 polyunsaturated fatty acids may increase endocannabinoid 
levels by providing additional substrate for FAAH, an enzyme that degrades anandamide 
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(Matias et al., 2006).  As previously mentioned, FAAH lacks the kind of substrate 
specificity that is characteristic of MAGL (Dinh et al., 2002).  As such, FAAH has been 
shown to hydrolyze the amide bond of not only anandamide, but also several other 
common amines formed from long-chain fatty acids (Schmid et al., 1985; Ueda et al., 
1995).  Interestingly, chocolate contains two such fatty-acid amides (N-oleoythanolamine 
and N-linoleoylethanolmine) that have been shown to inhibit the hydrolysis of 
anandamide in brain cells, possible by acting as a substrate for FAAH (Di Tomaso et 
al.,1996).
Even short-term consumption (e.g., 1 week) of diets rich in unsaturated fatty acids 
can elevate brain levels of long-chain fatty acids (N-acylethanolamines) as well as 
endocannabinoids (Artmann et al., 2008). The rats used in this study were fed diets rich 
in either monounsaturated fats (i.e., olive oil) or polyunsaturated fats (i.e., safflower oil). 
A diet rich in safflower oil may produce elevated levels of N-oleoythanolamine (OEA), 
N-linoleoylethanolamine (LEA) and 2-AG, while a diet rich in olive oil may also produce 
elevated brain-levels of anandamide as well.  
There is some evidence that the density of CB1 receptors in some brain regions
increases soon after mice are placed on a high-fat diet, but then CB1 density declines after 
sustained consumption of that diet (South and Huang, 2008). After 3 weeks, animals on 
the high-fat diet displayed elevated CB1 receptor density in the medial and ventral 
anterior olfactory nucleus, the agranular insular cortex and the hypothalamus when 
compared to animals maintained on a low-fat, high carbohydrate diet.
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The increase CB1 receptor density among the mice fed a high-fat diet was 
correlated with an increase in plasma leptin in the hypothalamus.  Leptin is a circulating 
hormone released primarily by white adipose tissue (Zhang et al., 1994) that acts in 
rodents via hypothalamic receptors to inhibit feeding and increase energy-expenditure 
(Jequier, 2002). There is also an inverse relationship in the hypothalamus between 
exogenously administered leptin and both anandamide and 2-AG (DiMarzo et al., 2001).  
When mice were maintained on the high-fat diet for 20 weeks, they became 
obese, hyperphagic and displayed decreased CB1 receptor density in several reward-
related brain areas (i.e., substantia nigra, ventral tegmental area). Though the brain 
endocannabinoid levels were not measured in these experiments, these results are 
certainly consistent with increased endocannabinoid signaling after sustained 
consumption of a high-fat diet.
Other evidence suggests that mice maintained on a high-fat diet have increased 
hepatic anandamide levels, perhaps because of the competitive inhibition of FAAH by 
fatty-acid amides (Osei-Hyiaman et al., 2005). Animals maintained on a high-fat diet also 
had dramatically diminished levels of FAAH activity when compared to controls, even 
though all the animals appeared to be synthesizing the same level of enzyme. 
While endocannabinoid levels appear influenced by the types and quantities of 
polyunsaturated fats in the diet, high-fat diets may also be related to changes in CB1 
receptor density.  When mice were maintained on a high-fat diet long enough to induce 
obesity, CB1 receptor densities in the hippocampus, nucleus accumbens and 
entopeduncular nucleus declined (Harrold et al., 2002).  The researchers involved in this 
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experiment produced their high-fat diet by supplementing normal rodent chow with 
Nestle condensed milk (PUFA content ranging 6%-36%; Harrold et al., 2002).  While the 
fat composition of the milk used in these experiments varied significantly, two-thirds of 
the polyunsaturated fatty acids in condensed milk are usually of the omega-6 variety 
(USDA National Nutrient Database for Standard Reference, 2005).  
In mice, sustained consumption of a high-fat diet that also contains elevated levels 
of cholesterol has been shown to reduce CB1 receptor density in the striatum and the 
hypothalamus (Hayakawa et al., 2007).  Curiously, chronic food restriction had the 
opposite effect. In these experiments, mice were divided into 3 groups: those receiving a 
normal diet, those receiving a restricted portion of a normal diet and those receiving a 
high-fat, cholesterol-enriched diet. After 6 weeks, both serum and brain cholesterol levels 
were determined and Western blots were used to determine the expression level of CB1
receptors in the cortex, the striatum and the hypothalamus. 
As expected, serum cholesterol levels significantly increased in the group fed the 
high-fat diet.  Conversely, striatal cholesterol levels significantly decreased and there was 
also a non-significant trend for cholesterol levels in the hypothalamus to decrease in that 
same group. Importantly, the level of CB1 receptor expression in the striatum also 
decreased significantly in the group that was fed the high-fat diet.
There is evidence that altering dietary fat intake can affect the composition of the 
cell membrane in general and, more specifically, change the composition of lipid rafts 
(Siddiqui et al., 2007).  Lipid rafts are small segments of the cell membrane that contain 
high-levels of cholesterol and sphingolipids  (Barnett-Norris et al., 2005). These small 
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pools of densely-packed saturated lipids move freely among the more loosely-packed 
unsaturated lipids that compose the cell membrane. Lipid rafts may permit some types of 
receptor proteins to coalesce (Melkonian et al., 1999) and increase signal transduction 
efficiency in the process (Moffett et al., 2000). It appears that lipid rafts influence 
binding and signaling at CB1 receptors (Barnett-Norris et al., 2005) and that the 
cholesterol content of the lipid raft may modulate the degree to which the receptor is 
activated by AEA (Bari et al., 2005).
Interestingly, while high-fat diets decrease CB1 receptor density in some areas of 
the brain, it may also increase CB1 receptor densities in the liver (Osei-Hyiaman, et al, 
2005).  While it is not yet clear why these differences CB1 receptor expression occur, 
they may be reflective of the peripheral role of cannabinoids as modulators of lipogenesis 
(Osei-Hyiaman et al., 2005, Loftus et al., 2001, Kim et al., 2002). 
While a mechanism for these changes in leptin, anandamide and CB1 receptors 
has not yet been demonstrated, it may be related to the various and sometimes disparate 
actions of endocannabinoids.  Taken together, these results suggest that diet-induced 
obesity results in elevated levels of circulating leptin. In response to increased leptin 
levels, endocannabinoid synthesis declines in the hypothalamus. This diminished 
endocannabinoid tone results in a short-term increase in CB1 receptor expression. If the 
high-fat diet is maintained for an extended period of time, however, anandamide levels 
rise because of the competitive inhibition of FAAH, or for some other yet unknown 
process. In response to the now elevated endocannabinoid tone, CB1 receptor expression 
is downregulated.
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The Development of Cannabinoid Tolerance
In vitro studies show that chronic treatment with cannabinoid agonists produces 
CB1 downregulation (i.e., loss of binding sites) and desensitization (i.e., loss of G-protein 
effector activity; Sim-Selley, 2003). The endocannabinoid system has a great deal of 
adaptive capacity and significant cannabinoid tolerance can develop, even with 
intermittent exposure to cannabinoids (Wiley et al., 1993). The changes in CB1 receptor 
density that occur after repeated exposure to exogenous cannabinoids like WIN 55,212-2 
or 9-tetrahydrocannabinol (Sim-Selley and Martin, 2002) are similar to the changes in 
CB1 receptor density that are associated with the sustained consumption of a high-fat diet 
(Harrold et al, 2002).
Cannabinoid tolerance can also be measured in vivo.  Cannabinoids transiently 
reduce body temperature (hypothermia), suppress spontaneous activity, induce catalepsy 
(Wiley and Martin, 2003) and increase food consumption (hyperphagia; Wiley et al., 
2005).   When animals are repeatedly treated with exogenous cannabinoids like 9-
tetrahydrocannabinol, hypothermia diminishes, levels of spontaneous activity return 
toward the baseline, catalepsy wanes (Fan et al., 1994), and hyperphagia dissipates (Jarbe 
and Di Patrizio, 2005). 
Like most psychoactive drugs, cannabinoids can produce context-specific 
tolerance through Pavlovian conditioning (Hill et al., 2004). The pharmacological effects 
of cannabinoids serve as an unconditioned stimulus and the environment in which those 
effects are experienced can serve as a conditioned stimulus. When the pharmacological 
effects of a drug are repeatedly and exclusively paired with a particular environment (i.e., 
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a behavioral pharmacology lab), context-specific (or behavioral) tolerance can develop. 
In this phenomenon, the conditioned stimulus acquires the ability to elicit compensatory 
responses that diminish the effects of the drug in question. Though some of the most 
striking examples of context-specific tolerance involve opioids (Siegel, 1976), similar 
results can be observed with repeated exposure to any psychoactive drug under the 
correct conditions.
A nascent body of evidence suggests that sustained consumption of a high-fat diet 
is related to region-specific reductions of CB1 receptor expression in the brain. This 
reduction in CB1 receptor density is similar to changes that are observed in rodents made 
tolerant to cannabinoids. It is not clear, however, whether the receptor changes observed 
after sustained consumption of a high-fat diet are behaviorally or physiologically 
relevant. Because of the nature of these CB1 receptor changes, it is hypothesized that rats 
maintained on a high-fat diet will be less sensitive to some or all of the pharmacological 
effects of 9-THC. Because of sex-related differences in cannabinoid responses, it is also 
hypothesized that diet-related behavioral and physiological in cannabinoid pharmacology 
will be more evident in female rats than in male rats.
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Method
Animals
All of the research in this proposal was conducted on male and female Long-Evans rats 
(Harlan Labs, Dublin, Virginia). All rats were single-housed in 11” X 17” X 8” Makrolon 
cages in a temperature-controlled (20oC–22oC) environment with 12-hour light and dark 
cycle (lights on at 6:00 am).  Water and the appropriate type of rodent chow were freely 
available in the home cages.  Food consumption and bodyweight were recorded twice 
each week and average daily food intake and weight change was calculated.  Each of 
these studies was carried out in accordance with the Guide for the Care and Use of 
Laboratory Animals (National Research Council, 1996) and was approved by the 
Virginia Commonwealth University Institutional Animal Care and Use Committee. 
Virginia Commonwealth University is an AAALAC accredited institution.
Diet
The high-fat diet used in these experiments was made by enriching standard 
rodent chow (Harlan Teklad Diet LM-485) with corn oil.  The standard rodent chow was 
soaked in room-temperature corn oil (20oC-22oC) for 24 hours before being drained and 
dried on clean paper towels. Once prepared, the diet was sealed in plastic bags 
immediately and stored at 4oC for a duration of no more than 7 days. Probe trials have
determined that when soaked for 24 hours in room-temperature corn oil, the resulting diet 
contained 4.63 kcal/g with 33.3% of those calories coming from fat (Fig. 1).  This diet 
was appropriate for these experiments because it was similar to diets used in related 
experiments that were performed in other labs and because it contained levels of fat that 
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Figure 1.  Fat content of high-fat diet. Unfortified chow derives 17% of digestible 
calories from fat. After soaking in corn oil at room temperature (20oC-22oC) for 24 
hours, fat content increases to 34.7% of digestible calories. Over the course of the 
following 4 days, 13% of the absorbed fat leeches from the chow. By the 5th day after 
soaking, fat content stabilizes. The average percentage of calories derived from fat 
over the shelf life of the food (7 days) is 33.3%.
are similar to the dietary intake of fat of the U.S. population (Kennedy et al., 1999). 
In contrast, rats fed the control diet (Harlan Teklad Diet LM-485; 3.75 kcal/g) 
derived 17% of their caloric intake from fat. The food for the control animals was kept in 
a sealed container that was maintained at room temperature (20oC-22oC) until dispensed 
into the feeding hopper in the home cage. In order to control for inter-group differences 
in the freshness of the food, the standard chow was replenished at the same rate as the 
high-fat chow (e.g., once every 7 days).
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Drugs
Delta-9-THC was obtained from the Drug Supply Program of the National 
Institute on Drug Abuse and dissolved in a solution of Tween 80 (7.8%) and 
physiological saline (92.2%). All injections of 9-THC were administered 
intraperitoneally at a volume of 1 ml/kg, with the exception the 70 mg/kg dose. The 70 
mg/kg dose was derived from a 35 mg/ml solution and was administered at a volume 2 
ml/kg.
Apparatus
Clear plastic cages (44 cm in length X 22.5 cm in width X 20 cm in height) 
covered with ventilated lids and housed in sound-attenuating cabinets were used as 
locomotor chambers. The chambers did not contain bedding and were cleaned with an 
alcohol solution between sessions. The sessions were conducted in near dark conditions 
as the cabinet doors were closed. A cage rack system with photocell beams along the x-
axis (8 beams) and y-axis (4 beams; Lafayette Instrument, Lafayette, IN) were placed 
around each chamber and positioned 4.5 cm above the chamber floor. Locomotor activity 
was measured as total number of beams broken during the 5-minute session.
A Traceable® digital thermometer (Control Company, Friendsville, TX) equipped 
with a flexible, plastic-coated probe was used to measure rectal temperature.  Probes 
measuring 1.5 mm in diameter were used for determining temperatures in adolescent rats 
(e.g., PD30 and PD44) and probes 3.5 mm in diameter were used for adult rats (e.g., 
PD68 and PD 114).
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The bar apparatus that was used to measure catalepsy-like behavior consisted of a 
280-mm long bolt (12.5 mm in diameter) that was attached to a vertical frame by 
eyebolts. The height of the bar was adjusted based upon the age of the rat (80 mm high at 
PD30, 100 mm high at PD44, and 130 mm at PD68 and PD114). To reduce the influence 
of extraneous stimuli, each bar apparatus was enclosed on the back, top and sides.  The 
cardboard enclosure was open in the front to permit access for the experimenter. Unlike 
the locomotion sessions, which were conducted in near dark conditions, rectal 
temperature and performance on the bar apparatus will be measured under normal indoor 
fluorescent lighting conditions.
Procedure
Females. A group of female Long-Evans rats (n = 9), was fed a high-fat diet (4.63 
kcal/g; 33% of calories from fat) beginning at postnatal day 30 (PD30).  A separate group 
of female Long-Evans rats (n = 9) was fed a control diet (3.75 kcal/g; 17% of calories 
from fat) for the duration of these experiments.  For female rats, cannabinoid activity was 
assessed in a triad of measures (hypothermia, catalepsy and spontaneous activity) on 
PD30, PD44, PD68, and PD114. These test points correspond to animal models of early 
adolescence, late adolescence, early adulthood and full maturity, respectively.
In order to obtain a full dose-effect curve in each rat, 9-THC was administered in 
a cumulative dosing procedure (0, 3, 10, 30 and 100 mg/kg) on each of these days (Table 
1).  The cumulative dosing sessions began with the determination of body weight and 
baseline body temperature followed by an intraperitoneal injection of vehicle.  
Temperature was measured by inserting a rectal thermometer probe 40 mm (adolescents) 
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or 45 mm (adults) into the rectum. The probe was dipped in mineral oil maintained at 
37oC for lubrication before insertion into the rectum. The rats were then returned to their 
home cages for 20 minutes. When 20 minutes had elapsed, the rats were placed in a 
locomotion chamber for 5 minutes.
       Table 1
        Cumulative dosing matrix
Time (mins) Procedure
-5 Baseline Body Temperature
0 Vehicle Injection
20 Locomotion
25 Body Temperature
30 Time on Bar Apparatus
35 3 mg/kg THC Injection
55 Locomotion
60 Body Temperature
65 Time on Bar Apparatus
70 7 mg/kg THC Injection
90 Locomotion
95 Body Temperature
100 Time on Bar Apparatus
105 20 mg/kg THC Injection
125 Locomotion
130 Body Temperature
135 Time on Bar Apparatus
140 70 mg/kg THC Injection
160 Locomotion
165 Body Temperature
170 Time on Bar Apparatus
During the locomotion session, measures of fine movement (i.e., breaking a single 
beam that lies adjacent to the rat’s position) and ambulatory movement (i.e., breaking two 
or more beams as the rat moves across the chamber floor) were recorded.  The software 
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that recorded movement in the chamber automatically discounted rapid, successive 
interruptions of the same beam because these types of data are indicative of stereotypic 
behavior and were not included in the measure of gross locomotion. The system also 
quantified movement along the periphery of the chamber as well as movement near the 
center of the chamber.
At the end of the locomotion session, body temperature was measured again and 
then the rats were immediately placed on the bar apparatus for up to 5 minutes. During 
the 5-minute bar apparatus session, the total amount of time (in seconds) that the front 
paws of a rat remained in contact with the bar was recorded. If both of the paws dropped 
from the bar, the animal was repositioned as before. The session timer was stopped 
briefly while the animal was repositioned. If the rat voluntarily removed both paws from 
the bar 10 times during the session, the session was be stopped, and amount of time spent 
with both paws on the bar was recorded as “zero”. Each rat was tested in all three of these 
procedures. The total amount of time required for these measures was no more than 15 
minutes (i.e., 5 minutes in the locomotion chamber plus 5 minutes on the bar apparatus 
plus time required for measurement of body temperature).
Immediately after the end of the bar apparatus session, the rats were injected 
intraperitoneally with a 3 mg/kg dose of 9-THC and returned to their home cage. When 
20 minutes had elapsed, the entire triad of measures was repeated. These measures were 
taken 3 more times after the rats have received successive intraperitoneal injections of 7 
mg/kg, 20 mg/kg and 70 mg/kg 9-THC. By using this method, a full dose-effect curve 
(0-100 mg/kg 9-THC) was generated for all of the rats at each age point.
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On postnatal day 128, 9-THC-induced antinociception was measured with a 
radiant-heat, tail-flick analgesia meter (Model #1430, Columbus Instruments, Columbus, 
OH). The animals were weighed and injected intraperitoneally with vehicle (92.2% 
saline, 7.8% Tween 80) and returned to their home cage.  After 30 minutes, latency to 
flick their tail away from the heat source was measured.  Immediately after this baseline 
response was recorded, the animals were injected intraperitoneally with 9-THC (30 
mg/kg) and again returned to their home cage. After another 30 minutes had elapsed, a 
second tail-flick measurement was taken.  
Subsequently, experiments were conducted to examine how 9-THC affected 
food intake.  In order to avoid carry-over effects, the first of the feeding trials was 
conducted fourteen days after the antinociception session (postnatal day 142). The rats 
were allowed ad libitum access to their normal food and water until they were weighed 
and injected intraperitoneally with 9-THC. These studies will be conducted under free-
feeding conditions because the high feeding rates that are commonly seen in food-
deprived rats can obscure drug effects (Williams and Kirkham, 2002).
Once initiated, feeding trials were conducted every 7 days until all doses of 9-
THC (0, 0.3, 1, 3, 10 and 30 mg/kg) were tested. The various doses of 9-THC were 
delivered a randomized order (modified Latin squares) so that drug dose did not vary 
systematically with age. After treatment with 9-THC, the rats were returned to their 
home cage for 30 minutes. All of the food was removed from the home cage at this time. 
After the 30-minute pretreatment time had elapsed, a pre-weighed portion of the normal 
food (i.e., standard chow for rats on the control diet and high-fat chow for rats on the 
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high-fat diet) was placed in the home cage. After 1 hour, the food portion was removed, 
weighed and immediately returned to the cage. This procedure was repeated after another 
hour had elapsed. The food portion was removed and weighed again after 3 hours had 
elapsed and the total mass of food consumed during the feeding trial was recorded.
Males. A group of male Long-Evans rats (n = 9), was fed a high-fat diet (4.63 
kcal/g; 33% of calories from fat) beginning at postnatal day 30 (PD30).  A separate group 
of male Long-Evans rats (n = 9) was fed a control diet (3.75 kcal/g; 17% of calories from 
fat) for the duration of these experiments.  For male rats, cannabinoid activity was 
assessed in a triad of measures (hypothermia, catalepsy and spontaneous activity) on 
PD30, PD37, PD44, PD61, PD68, and PD114. The procedure utilized at each of these age 
points was identical to the procedure for the described for the female rats.  By using this 
method, a full dose-effect curve (0-100 mg/kg 9-THC) was generated for all of the rats 
at each age point.
Subsequently, experiments were conducted to examine how 9-THC affected 
food intake.  In order to avoid carry-over effects, the first of the feeding trials was 
conducted fourteen days after the last cumulative dosing session (postnatal day 128). 
These feeding trials were conducted under both free-fed conditions and after 24 hours of 
food deprivation. Once initiated, feeding trials were conducted every 7 days until all 
doses of 9-THC (0, 0.3, 1, 3, and 10 mg/kg) were tested under each condition. The 
nutritional status of the rats (food-deprived vs. free-fed) and the various doses of 9-THC 
were delivered a randomized order so that neither condition nor drug dose varied 
systematically with age.
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After treatment with 9-THC, the rats were returned to their home cage for 30 
minutes. All of the food was removed from the home cage at this time. After the 30-
minute pretreatment time had elapsed, a pre-weighed portion of the normal food (i.e., 
standard chow for rats on the control diet and high-fat chow for rats on the high-fat diet) 
was placed in the home cage. After 1 hour, the pre-weighed portion of food was removed, 
weighed and the total mass of food consumed during the feeding trial was recorded.
When the male rats were aged 19 months, 9-THC-induced antinociception was 
measured with a radiant-heat, tail-flick analgesia meter (Model #1430, Columbus 
Instruments, Columbus, OH). The procedure for measuring the antinociceptive properties 
of 9-THC in male rats was the same as the above-described procedure that was used 
with the female rats. 
Two separate groups of male rats (n = 4) were used to explore the possibility that 
context-specific (or behavioral) tolerance affected the repeated measures that are intrinsic 
to this experimental design (Table 1). For each group, 9-THC-induced hypothermia was 
measured in a cumulative dosing procedure (0-100 mg/kg) on postnatal day 30 and again 
on postnatal day 37. For the first group, both of these experiments was conducted in an 
identical environment (e.g., the same behavioral pharmacology lab). For the second 
group of rats, the two experiments were conducted in two disparate environments (e.g., a 
behavioral pharmacology lab and in the vivarium).
Data Analysis
Sample size for each experiment was determined with SigmaStat (ver. 3.5; Systat
Software Corporation, Point Richmond, CA).  Parameters entered in this program
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included effect size, standard deviation, number of groups, desired power, and alpha 
level.  Values for the proposed studies, a small-to-medium effect size (0.15; Cohen et al., 
      
     Table 2
       Methodology for Examining Context-specific Tolerance
Location of 1st Test Location of 2nd test
Group 1
Behavioral 
Pharmacology Lab
Behavioral 
Pharmacology Lab
Group 2
Behavioral 
Pharmacology Lab
Vivarium
2003) was chosen for the power analysis.  Based on standard deviations derived from 
probe trials, the standard deviation for these calculations will be estimated at 0.125.  By 
convention, the desired power level will be set at 0.80 and the alpha level will be set at 
0.05 (Howell, 1997). 
SigmaStat calculated that a sample size of 9 per group was necessary in order to 
detect differences based on these parameters.  This sample size was consistent with sizes 
used by this lab previously in similar studies and was used for all studies in this protocol.  
In total, 44 animals were required to complete these studies.  These studies commenced 
on postnatal day 30 for both male and female rats and and concluded on postnatal day 
190 for female rats and on or about postnatal day 578 for male rats. 
All statistical analyses, except ED50 calculations, were conducted using SigmaStat 
statistical software.  GraphPad Prism was used to determine ED50 values and 95% 
32
confidence limits as necessary. Growth rates were compared by linear regression 
analysis.  Bodyweights, average daily food consumption, hypothermia, locomotor 
activity, time with paws on bar apparatus, tail-flick latencies and food-intake were 
analyzed with a split-plot ANOVA.  The development of context-specific tolerance was 
analyzed with a two-factor (dose, location of second test), repeated measures ANOVA. 
Changes in tail-flick latency were be analyzed with a one-factor (diet) ANOVA. Tukey 
post hoc tests ( = 0.05) will be used to specify differences revealed by significant 
ANOVAs. The diet-related changes in potency of 9-THC(ED50 values and 95% 
confidence limits) were determined by fitting a non-linear regression equation against the 
corresponding dose-effect curve. Each measurement was plotted against the common 
logarithm of the dose. In order to determine the ED50 values for 9-THC, the amount of 
time with paws on bar apparatus was expressed as a percentage of the total session length 
(300 seconds).  Similarly, locomotor activity at various doses of 9-THC was expressed 
as a percentage of baseline locomotor activity.
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Results
Effects of a High-fat Diet on Bodyweight
Females. As expected, female rats gained a significant amount of weight over the 
course of development [main effect of postnatal day, F(26, 416) = 301.204, p < 0.001].  
Further, female rats fed a high fat diet overall weighed significantly more than those fed a 
control diet [main effect of diet, F(1, 16) = 37.483, p < 0.001], (Fig. 2). A significant 
interaction between diet and postnatal day on bodyweights was not detected, F(26, 416) = 
0.9136, p < 0.590. 
Males. Male rats also exhibited a significant main effect of diet on bodyweight, 
F(1, 15) = 126.804, p < 0.001, with those fed a high fat diet being heavier, as well as a 
significant main effect of postnatal day on bodyweight, F(26, 390) = 671.428, p < 0.001 
(Fig. 3). No significant interaction between diet and postnatal day on bodyweight was 
detected, F(26, 390) = 0.7885, p = 0.7631. 
Psychomotor Effects – Time on Bar Apparatus 
Females. Baseline measurements of the amount of time female rats spent on the 
bar apparatus were conducted on postnatal day 30. At baseline, there was a significant 
main effect of 9-THC on the amount of time spent on the bar apparatus, F(4, 64) = 
85.164, p < 0.001 (Fig. 4). When tested on postnatal day 30, both groups of rats spent 
significantly more time on the bar apparatus when treated with 10 mg/kg, 30 mg /kg and
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Figure 2. Growth chart for female rats. Despite the presence of significant main 
effects of diet and postnatal day on bodyweight, no significant interactions of diet and 
postnatal day on bodyweight were detected.
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Figure 3. Growth chart for male rats. Despite the presence of significant main effects 
of diet and postnatal day on bodyweight, no significant interactions of diet and 
postnatal day on bodyweight were detected.
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100 mg/kg doses of 9-THC than when treated with vehicle (p < 0.05 for all measures). 
In contrast, a 3 mg/kg dose of 9-THC did not significantly increase the amount of time 
the rats spent on the bar apparatus. However, there was no significant main effect of diet 
on the amount of time spent on bar apparatus, F(1, 16) = 0.593, p = 0.452 and no 
significant interaction between diet and dose of 9-THC was detected, F(4, 64) = 0.606,  
p = 0.659.
The results for the amount of time female rats spent on the bar apparatus at 
postnatal day 44 were similar to the results observed on postnatal day 30. At postnatal 
day 44, there was again a significant main effect of 9-THC on the amount of time spent 
on the bar apparatus, F(4, 64) = 123.167, p < 0.001 (Fig. 5). Both groups of rats spent 
significantly more time on the bar apparatus when treated with 10 mg/kg, 30 mg/kg and 
100 mg/kg doses of 9-THC than when treated with vehicle (p < 0.05 for all measures). 
Again, a 3 mg/kg dose of 9-THC did not significantly increase the amount of time the 
rats spent on the bar apparatus when tested at postnatal day 44. There was no main effect
of diet on the amount of time spent on bar apparatus, F(1,16) = 2.806, p = 0.113) and no
significant interaction between diet and dose of 9-THC was detected, F(4, 64) = 1.384, 
(p = 0.250).
By postnatal day 68, however, significant diet-related differences in the amount of 
time spent on the bar apparatus became apparent (Fig. 6). Analyses revealed a significant
interaction between the type of diet consumed and the dose of 9-THC administered, F(4, 
64) = 2.685,  p = 0.039. At this age point, the amount of time that female rats spent with 
their paws on the bar apparatus after treatment with 9-THC was dependent upon which 
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Figure 4.  Time on bar apparatus for female rats at PD30. Expressed as percentage of 
the total session time (mean +/- SEM) that female rats remained on the bar apparatus 
at postnatal day 30.  While 9-THC produced a significant, dose-dependent increase in 
time on the bar apparatus, the groups exhibited indistinguishable drug responses. Data 
points highlighted with an “#” are significantly different from the respective vehicle-
treated conditions.
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Figure 5.  Time on bar apparatus for female rats at PD44. Expressed as percentage of 
the total session time (mean +/- SEM) that female rats remained on the bar apparatus 
at postnatal day 44.  While 9-THC continued to produce a significant, dose-
dependent increase in time on the bar apparatus, no between group differences were 
noted. Data points highlighted with a “#” are significantly different from the 
respective vehicle-treated conditions.
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Figure 6.  Time on bar apparatus for female rats at PD68. Expressed as a percentage
of the total session time (mean +/- SEM) that female rats remained on the bar
apparatus at postnatal day 68.  A significant interaction between 9-THC and the
type of diet consumed was evident. Though 9-THC continued to produce a 
significant, dose-dependent increase in time on the bar apparatus for both groups, 
the female rats maintained on a high-fat diet spent significantly less time on the bar
apparatus than the female rats maintained on the control diet when treated with 30 
mg/kg and 100 mg/kg doses of 9-THC. Data points highlighted with “#” are 
significantly different from the respective vehicle-treated conditions. Data points 
highlighted with asterisk are significantly different from each other. (“*” indicates
p < 0.05; “**” indicates p < 0.01.)
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diet they consumed. Although 9-THC produced a dose-dependent increase in the 
amount of time spent on the bar apparatus in both groups, the rats that were maintained 
on a high-fat diet spent significantly less time on the bar apparatus than did the rats 
maintained on the control diet when treated with 30 mg/kg and 100 mg/kg doses of 9-
THC (p < 0.05 for both measures).  Despite these differences in the amount of time spent 
on the bar apparatus at postnatal day 68, the 95% confidence intervals for the ED50 values 
of 9-THC overlapped (Table 3), indicating the absence of diet-related differences in the 
potency of 9-THC.
Table 3
Potency of 9-THC in female rats. 
Females PD30 PD44
HFD Control HFD Control
Bar 
Apparatus
ED50
(mg/kg) 12 15.7 12.9 10.3
95% CI 
(mg/kg)
10.7-
13.4
13.4-
18.4
11.5-
14.4
8.1-
13.0
Locomotor 
Activity
ED50
(mg/kg) 147.8 46.3 n/a 2499
95% CI 
(mg/kg)
19.5-
1121
17.0-
126.6 n/a n/a
PD68 PD114
HFD Control HFD Control
Bar 
Apparatus
ED50
(mg/kg) 11.5 6.9 25.1 5.2
95% CI 
(mg/kg)
8.8-
14.9 4.9-9.7
20.6-
30.6 3.5-7.7
Locomotor 
Activity
ED50
(mg/kg) 38 29.4 9.4 9.4
95% CI 
(mg/kg)
27.1-
53.2
1.9-
466.2
5.1-
17.2
5.1-
17.2
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When tested on postnatal day 114, the diet-related differences in the amount of 
time spent on the bar apparatus were again obvious (Fig. 7). Analyses revealed a 
significant interaction between the type of diet consumed and the dose of 9-THC 
on the amount of time spent with forepaws on the bar apparatus, F(4, 64) = 6.875,  p < 
0.001. Again, 9-THC produced a dose-dependent increase in the amount of time spent 
on the bar apparatus in both groups. Rats maintained on a high-fat diet spent significantly 
less time on the bar apparatus than did the rats maintained on the control diet when 
treated with 10 mg/kg 9-THC and 30 mg/kg 9-THC (p < 0.05 for both measures). On 
postnatal 114, the 95% confidence intervals for the ED50 values of 9-THC did not 
overlap (Table 3). At this age point, 9-THC was significantly less potent in the rats 
maintained on a high-fat diet than in the rats maintained on a control diet.
Even though there were significant inter-group differences in the amount of time 
spent on the bar apparatus after postnatal day 68, other non-systematic observations 
suggest that the measurements used in these experiments may underestimate the 
differences between the groups (Fig. 8).  At doses of 9-THC above 10 mg/kg, the female 
rats fed the control diet typically moved their heads and forepaws very little and appeared 
quite sedated while on the bar apparatus. At those same doses, the female rats fed a high-
fat diet typically moved their heads, usually changed their posture at least once during the 
course of the 5-minute session on the bar apparatus and frequently re-positioned their 
paws or moved along the bar apparatus. At doses of 9-THC above 30 mg/kg, female rats 
fed a high-fat diet commonly engaged in a series of repetitive head 
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Figure 7. Time on bar apparatus for female rats at PD114. Percentage of the total 
session time (mean +/- SEM) that female rats remained on the bar apparatus at 
postnatal day 114.  A significant interaction between 9-THC and the type of diet 
consumed was evident. Though 9-THC continued to produce a significant, dose-
dependent increase in time on the bar apparatus for both groups, the female rats 
maintained on a high-fat diet spent significantly less time on the bar apparatus than the 
female rats maintained on the control diet when treated with 10 mg/kg and 30 mg/kg 
doses of 9-THC. Data points highlighted with “#” are significantly different from the 
respective vehicle-treated conditions. Data points highlighted with asterisk are 
significantly different from each other. (“*” indicates p < 0.05; “***” indicates p < 
0.001.)
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Figure 8.  Differences in activity during bar apparatus sessions. Non-systematic 
observations suggest that the female rats maintained on a high-fat diet were 
significantly less affected by moderate and high doses of 9-THC than were female 
rats maintained on the control diet. These photos were taken after the rats had been 
treated with a 10 mg/kg dose of 9-THC. The female rat maintained on a high-fat diet 
(right) frequently exhibited overt head movements, shifts in posture and lateral 
movements along the bar apparatus. The female rat maintained on the control diet 
(left) was virtually immobile. These differences in activity were not captured by the 
operational definition the dependent variable because the front paws rarely the left bar 
apparatus while the rat maintained on a high-fat diet executed these movements.
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movements. These movements were typically from side-to-side and were occasionally 
accompanied by a slight shift in posture or body position.
In general, there were no differences between the groups in the amount of time 
spent on the bar apparatus until the female rats reached early adulthood (postnatal day 
68). After postnatal day 68, the female rats maintained on the high-fat diet were 
significantly less sensitive to 9-THC-induced increases in the amount of time spent on 
the bar apparatus.
Males. Like the female rats, baseline measures of time spent on the bar apparatus 
for the male rats were taken on postnatal day 30. At baseline, there was a significant main 
effect of 9-THC on the amount of time spent on the bar apparatus, F(4, 64) = 115.781, p
< 0.001 (Fig. 9). Both groups of male rats spent significantly more time on the bar 
apparatus when treated with 10 mg/kg, 30 mg/kg and 100 mg/kg doses of 9-THC than 
when treated with vehicle (p < 0.05 for all measures). A 3 mg/kg dose of 9-THC, 
however, did not significantly increase the amount of time the male rats spent on the bar 
apparatus. There was no main effect of diet on the amount of time spent on bar apparatus, 
F(1, 16) = 0.0534, p = 0.820 and no significant interaction between diet and dose was 
detected, F(4, 64) = 0.0137, p = 1.000.
When the male rats were tested at postnatal day 37, the significant main effect of 
9-THC on the amount of time spent on the bar apparatus persisted, F(4, 60) = 50.829, p
< 0.001 (Fig. 10). Male rats maintained on the control diet spent significantly more time 
on the bar apparatus when treated with 10 mg/kg, 30 mg/kg and 100 mg/kg doses of 9-
THC than when treated with vehicle (p < 0.05 for all measures). Male rats maintained on 
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Figure 9.  Time on bar apparatus for male rats at PD30. Percent of the total session 
time (mean +/- SEM) that male rats remained on the bar apparatus at postnatal day 30.  
Though 9-THC to produce a significant, dose-dependent increase in time on the bar 
apparatus, the groups were again indistinguishable in terms of their responses. Data 
points highlighted with a “#” are significantly different from the respective vehicle-
treated conditions.
46
a high-fat diet spent significantly more time on the bar apparatus when treated with 30 
mg/kg and 100 mg/kg doses of 9-THC than when treated with vehicle (p < 0.05 for both 
measures). A 3 mg/kg dose of 9-THC did not significantly increase the amount of time 
the rats spent on the bar apparatus for either group. At postnatal day 37, like at postnatal 
day 30, there was no main effect of diet on the amount of time spent on bar apparatus 
F(1, 15) = 0.203, p = 0.659) and no significant interaction between diet and dose was 
detected, F(4, 60) = 0.419, p = 0.795.
When the male rats were tested at postnatal day 44, there was again a significant 
main effect of 9-THC on the amount of time spent on the bar apparatus, F(4, 60) = 
30.387, p < 0.001 (Fig. 12). Male rats maintained on the control diet spent significantly 
more time on the bar apparatus when treated with 30 mg/kg and 100 mg/kg doses of 9-
THC than when treated with vehicle (p < 0.05 for both measures). Like previous tests, a 3 
mg/kg dose of 9-THC failed to significantly increase the amount of time the rats spent 
on the bar apparatus. Also like previous tests with male rats, there was no main effect of 
diet on the amount of time spent on bar apparatus F(1, 15) = 0.00198, p = 0.965) and no 
significant interaction between diet and dose was detected, F(4, 60) = 1.316, p = 0.275.
When the male rats were tested at postnatal day 61, the significant main effect of 
9-THC on the amount of time spent on the bar apparatus was still apparent, F(4, 60) = 
36.510, p < 0.001 (Fig. 13). Both groups of male rats diet spent significantly more time 
on the bar apparatus when treated with 10 mg/kg, 30 mg/kg and 100 mg/kg doses of 9-
THC than when treated with vehicle (p < 0.05 for all measures). A 3 mg/kg dose of 9-
THC did not significantly increase the amount of time the rats spent on the bar apparatus 
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Figure 10.  Time on bar apparatus for male rats at PD37. Percent of the total session 
time (mean +/- SEM) that male rats remained on the bar apparatus at postnatal day 37.  
Just as at PD30, 9-THC produced a significant, dose-dependent increase in time on 
the bar apparatus, but the responses between the groups were again indistinguishable. 
Data points highlighted with a “#” are significantly different from the respective 
vehicle-treated conditions.
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Figure 11.  Time on bar apparatus for male rats at PD44. Percent of the total session 
time (mean +/- SEM) that male rats remained on the bar apparatus at postnatal day 44. 
While 9-THC continued to produce a significant, dose-dependent increase in time on 
the bar apparatus, the responses between the groups were again indistinguishable. Data 
points highlighted with an “#” are significantly different from the respective vehicle-
treated conditions.
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for either group. At postnatal day 61, there was no main effect of diet on the amount of 
time spent on bar apparatus F(1, 15) = 0.599, p = 0.451) and no significant interaction 
between diet and dose was detected, F(4, 60) = 0.555, p = 0.696.
For the male rats, the previously noted trends in the amount of time spent on the 
bar apparatus continued on postnatal day 68 (Fig. 13). At this age point, male rats 
displayed a significant main effect of 9-THC on the amount of time spent on the bar 
apparatus, F(4, 60) = 39.519, p < 0.001. Like the previous tests, both groups of male rats 
spent significantly more time on the bar apparatus when treated with 10 mg/kg, 30 mg/kg 
and 100 mg/kg doses of 9-THC than when treated with vehicle (p < 0.05 for all 
measures) and a 3 mg/kg dose of 9-THC did not increase the amount of time the rats 
spent on the bar apparatus significantly. There were again no main effect of diet on the 
amount of time spent on bar apparatus F(1, 15) = 0.0176, p = 0.896 and no significant 
interaction between diet and dose was detected, F(4, 60) = 0.578, p = 0.680.
When the male rats were tested on postnatal day 114, however, significant diet-
related differences in the amount of time spent on the bar apparatus were evident (Fig. 
14). At this age point, there was a significant interaction between the type of diet 
consumed and the dose of 9-THC administered, F(4, 60) = 8.230,  p < 0.001, with 9-
THC producing a significant dose-dependent increase in the amount of time spent on the 
bar apparatus in both groups. Male rats maintained on a high-fat diet spent significantly 
less time on the bar apparatus than did the rats maintained on the control diet when 
treated with 10 mg/kg 9-THC (p < 0.05). On postnatal 114, 9-THC also appeared to be 
significantly less potent in the male rats maintained on a high-fat diet than in the male 
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Figure 12.  Time on bar apparatus for male rats at PD61. Percent of the total session 
time (mean +/- SEM) that male rats remained on the bar apparatus at postnatal day 61. 
While 9-THC continued to produce a significant, dose-dependent increase in time on 
the bar apparatus, the responses between the groups were again indistinguishable. Data 
points highlighted with a “#” are significantly different from the respective vehicle-
treated conditions.
51
Males - PD68
VEH
0%
25%
50%
75%
100% High-fat Diet
Control Diet
3 10 30 100
#
#
#
#
#
#
9-THC (mg/kg)
Ti
m
e 
o
n
 B
a
r 
A
p
p
ar
a
tu
s 
(%
 o
f 
S
e
s
si
o
n
)
Figure 13.  Time on bar apparatus for male rats at PD68. Percent of the total session 
time (mean +/- SEM) that male rats remained on the bar apparatus at postnatal day 68. 
While 9-THC continued to produce a significant, dose-dependent increase in time on 
the bar apparatus, the responses between the groups were again indistinguishable. Data 
points highlighted with a “#” are significantly different from the respective vehicle-
treated conditions.
52
VEH
0%
25%
50%
75%
100% High-fat Diet
Control Diet
3 10 30 100
Males - PD114
***
#
#
#
#
#
9-THC (mg/kg)
T
im
e
 o
n 
B
ar
 A
p
p
ar
at
u
s 
(%
 o
f 
S
e
s
si
o
n)
Figure 14.  Time on bar apparatus for male rats at PD114. Percentage of the total 
session time (mean +/- SEM) that male rats remained on the bar apparatus at postnatal 
day 114.  A significant interaction between 9-THC and the type of diet consumed 
was evident. Though 9-THC continued to produce a significant, dose-dependent 
increase in time on the bar apparatus for both groups, the male rats maintained on a 
high-fat diet spent significantly less time on the bar apparatus than the male rats 
maintained on the control diet when treated with a 10 mg/kg dose of 9-THC. Data 
points highlighted with a “#” are significantly different from the respective vehicle-
treated conditions. Data points highlighted with asterisk are significantly different 
from each other. (“***” indicates p < 0.001.)
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rats maintained on a control diet. The 95% confidence intervals for the ED50 values of 9-
THC did not overlap (Table 4).
       Table 4
       Potency of 9-THC in male rats. 
Psychomotor Effects – Gross Locomotor Activity
Females. Baseline measures for gross locomotor activity in female rats were taken 
on postnatal day 30. At baseline, there was a significant main effect of 9-THC on the 
Males PD30 PD37 PD44
HFD Control HFD Control HFD Control
Bar 
Apparatus
ED50 
(mg/kg)
14.3 15.3 22.5 11.0 15.6 6.4
95% CL 
(mg/kg)
11.8-17.3 12.8-18.4 19.1-26.5 9.3-13.1 12.3-19.9 4.5-9.2
Locomotor 
Activity
ED50 
(mg/kg)
6.2 12.5 n/a n/a n/a n/a
95% CL 
(mg/kg)
4.3-9.1 8.6-18.3 n/a n/a n/a n/a
          PD61           PD68           PD114
HFD Control HFD Control HFD Control
Bar 
Apparatus
ED50 
(mg/kg)
5.8 8.0 14.3 7.3 39.3 5.3
95% CL 
(mg/kg)
4.2-8.0 5.2-12.2 12.2-16.9 5.7-9.4 27.2-56.8 3.4-8.3
Locomotor 
Activity
ED50 
(mg/kg)
6.6 22.0 n/a 38.0 n/a 28.9
95% CL 
(mg/kg)
5.3-8.2 13.9-34.8 n/a 27.1-53.2 n/a 22.5-37.1
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number of beams broken during locomotor testing session, F(4, 64) = 23.764, p < 0.001 
(Fig. 15). Both groups of female rats broke fewer beams when treated with 30 mg/kg and 
100 mg/kg doses of 9-THC than when treated with vehicle (p < 0.05 for both measures).
A 3 mg/kg dose of 9-THC did not significantly affect the number of beams broken 
during the session. There was no main effect of diet on the number of beams broken F(1, 
16) = 0.0110, p = 0.918, and no significant interaction between the type of diet and the 
dose of 9-THC on the number of beams broken was detected F(4, 64) = 0.434,  p = 
0.783.
At postnatal day 44, the significant main effect of 9-THC on the number of 
beams broken persisted, F(4, 64) = 14.058, p < 0.001 (Fig. 16). Female rats broke 
significantly fewer beams when treated with a 100 mg/kg dose of 9-THC. There was no 
main effect of diet on the number of beams broken F(1, 16) = 1.910, p = 0.186 and no 
significant interaction between the type of diet and the dose of 9-THC on the number of 
beams broken was detected F(4, 64) = 1.043, p = 0.392.
By postnatal day 68, a significant interaction between the type of diet consumed 
and the dose of 9-THC on the number of beams broken was evident, F(4, 64) = 4.188,
p = 0.004 (Fig. 17). At this age, female rats maintained on a high-fat diet broke a 
significantly greater number of beams than did female rats maintained on a control diet 
when each group was treated with a 30 mg/kg and a 100 mg /kg dose of 9-THC (p < 
0.05 for both measures). For the females maintained on the control diet, the 95% 
confidence intervals for ED50 values of 9-THC were 27.1 to 53.2 mg/kg (Table 3). In 
contrast, it was not possible to calculate ED50 values under this dosing regimen for the 
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Figure 15.  Locomotor activity for female rats at PD30. Number of beams broken 
(mean +/- SEM) by female rats after treatment with 9-THC on postnatal day 30.
Delta-9-THC dose-dependently decreased locomotor activity in both groups. No 
between-group differences in drug response were detected. Data points highlighted 
with a “#” are significantly different from the respective vehicle-treated conditions.
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Figure 16.  Locomotor activity for female rats at PD44. Number of beams broken 
(mean +/- SEM) by female rats after treatment with 9-THC on postnatal day 44.
Again, 9-THC dose-dependently decreased locomotor activity in both groups. No 
between-group differences in drug response were detected. Data points highlighted 
with a “#” are significantly different from the respective vehicle-treated conditions.
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Figure 17.   Locomotor activity for female rats at PD68. Number of beams broken 
(mean +/- SEM) by female rats after treatment with 9-THC at postnatal day 68.  A 
significant interaction between 9-THC and diet on the number of beams broken was 
evident. Female rats maintained on the control diet broke significantly fewer beams 
than female rats maintained on a high-fat diet when treated with 30 mg/kg and 100 
mg/kg doses of 9-THC. Additionally, female rats maintained on the control diet 
broke significantly fewer beams when treated with a 100 mg/kg dose of 9-THC than 
when treated with vehicle. In contrast, the number of beams broken by female rats 
maintained on a high-fat diet never varied significantly from the number broken under 
vehicle conditions, regardless of the dose of 9-THC. Data points highlighted with “#” 
are significantly different from the respective vehicle-treated conditions. Data points 
highlighted with asterisk are significantly different from each other. (“*” indicates p < 
0.05; “**” indicates p < 0.01.)
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female rats maintained on a high-fat diet because the relationship between the dose of 9-
THC and locomotor activity was non-linear.
The significant interaction between the type of diet consumed and the dose of 9-
THC on the number of beams broken continued at postnatal day 114, F(4, 64) = 3.292,
p = 0.016 (Fig. 18). At doses of 3 mg/kg, 10 mg/kg and a 100 mg /kg of 9-THC, female 
rats maintained on a high-fat diet broke a significantly greater number of beams than did 
female rats maintained on a control diet (p < 0.05 for all measures). Despite this 
difference, the 95% confidence intervals for ED50 values of 9-THC overlapped (Table 3) 
Males. Like females, baseline measures for gross locomotor activity in male rats 
were taken on postnatal day 30. At baseline, there was a significant main effect of 9-
THC on the number of beams broken during a five-minute testing session, F(4, 64) = 
1.894, p < 0.001 (Fig. 19). Both groups of male rats broke fewer beams when treated with 
10 mg/kg, 30 mg/kg and 100 mg/kg doses of 9-THC than when treated with vehicle (p < 
0.05 for all measures). A dose of 3 mg/kg 9-THC did not significantly affect the number 
of beams broken during the session. At this age point, there was no main effect of diet on 
the number of beams broken, F(1, 16) = 0.000484, p = 0.983, and no significant 
interaction between the type of diet and the dose of 9-THC was detected, F(4, 64) = 
1.894, p = 0.122.
At postnatal day 37, changes in gross locomotor activity in male rats after 
treatment with 9-THC were similar to what was seen on postnatal day 30. There was a 
significant main effect of 9-THC the number of beams broken, F(4, 60) = 8.089, p < 
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Figure 18.  Locomotor activity for female rats at PD114. Number of beams broken 
(mean +/- SEM) by female rats after treatment with 9-THC at postnatal day 114.  A 
significant interaction between 9-THC and diet on the number of beams broken was 
evident. Female rats maintained on the control diet broke significantly fewer beams 
than female rats maintained on a high-fat diet when treated with 3 mg/kg, 10 mg/kg 
and 100 mg/kg doses of 9-THC. Female rats maintained on the control diet broke 
significantly fewer beams when treated with a 30 mg/kg and 100 mg/kg doses of 9-
THC than when treated with vehicle. Additionally, female rats maintained on a high-
fat diet broke a significantly larger number of beams when treated with a 3 mg/kg dose 
of 9-THC than with treated with vehicle. Data points highlighted with “#” are 
significantly different from the respective vehicle-treated conditions. Data points 
highlighted with asterisk are significantly different from each other. (“*” indicates p < 
0.05; “**” indicates p < 0.01.)
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0.001 (Fig. 20) with 10 mg/kg, 30 mg/kg and 100 mg/kg doses of 9-THC reducing the 
number of beams broken (p < 0.05). Analysis of the locomotor activity tests conducted 
on male rats at postnatal day 37 failed to detect a significant main effect of diet the 
number of beams broken, F(1, 15) = 0.0254, p = 0.876. Likewise, there was not a 
significant interaction between type of diet consumed and the dose of 9-THC, F(4, 60) = 
0.701, p = 0.595.
When tested on postnatal day 44, changes in gross locomotor activity after 
treatment with 9-THC were similar to what was seen on postnatal day 37. There was a 
significant main effect of 9-THC the number of beams broken, F(4, 60) = 6.131, p < 
0.001 (Fig. 21) with 10 mg/kg, 30 mg/kg and 100 mg/kg doses of 9-THC reducing the 
number of beams broken (p < 0.05). Analysis of the locomotor activity tests conducted 
on male rats at postnatal day 44 failed to detect a significant main effect of diet the 
number of beams broken, F(1, 15) = 0.828, p = 0.377.  Likewise, there was not a 
significant interaction between type of diet consumed and the dose of 9-THC, F(4, 60) = 
0.327, p = 0.859.
At postnatal day 61, the significant main effect of 9-THC on the number of 
beams broken during the locomotor sessions persisted, F(4, 60) = 19.865, p < 0.001 (Fig. 
22) with 10 mg/kg, 30 mg/kg and 100 mg/kg doses of 9-THC reducing the number of 
beams broken. No significant main effect of diet on the number of beams broken was 
noted, F(1, 15) = 0.0851, p = 0.775, and the interaction between the type of diet and dose 
of 9-THC was not significant, F(4, 60) = 1.137, p = 0.348.
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Figure 19.  Locomotor activity for male rats at PD30. Number of beams broken (mean 
+/- SEM) by male rats after treatment with 9-THC on postnatal day 30. Delta-9-THC
dose-dependently decreased locomotor activity in both groups. No between-group 
differences in drug response were detected. Data points highlighted with a “#” are 
significantly different from the respective vehicle-treated conditions.
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Figure 20.  Locomotor activity for male rats at PD37. Number of beams broken (mean 
+/- SEM) by male rats after treatment with 9-THC on postnatal day 37. A significant 
main effect of 9-THC on the number of beams broken was noted, No between-group 
differences in drug response were detected. Data points highlighted with a “#” are 
significantly different from the respective vehicle-treated conditions.
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Figure 21.  Locomotor activity for male rats at PD44. Number of beams broken (mean 
+/- SEM) by male rats after treatment with 9-THC on postnatal day 44. A significant 
main effect of 9-THC on the number of beams broken was noted, No between-group 
differences in drug response were detected. Data points highlighted with a “#” are 
significantly different from the respective vehicle-treated conditions.
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Figure 22.  Locomotor activity for male rats at PD61. Number of beams broken (mean 
+/- SEM) by male rats after treatment with 9-THC on postnatal day 61. A significant 
main effect of 9-THC on the number of beams broken was noted, No between-group 
differences in drug response were detected. Data points highlighted with a “#” are 
significantly different from the respective vehicle-treated conditions.
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At postnatal day 68, there was still a significant main effect of 9-THC on the 
number of beams broken during the locomotor sessions, F(4, 60) = 18.558, p < 0.001 
(Fig. 23). Locomotor activity was inhibited significantly 30 mg/kg and 100 mg/kg doses 
of 9-THC (p < 0.05 for both measures). No significant main effect of diet on the number 
of beams broken was noted, F(1, 15) = 0.0380, p = 0.848, and the interaction between the 
type of diet and dose of 9-THC was not significant, F(4,60) = 1.879, p = 0.126.
Similarly, at postnatal day 114, there was a significant main effect of 9-THC on 
the number of beams broken during the locomotor sessions, F(4, 60) = 4.453, p = 0.003 
(Fig. 24). However, 9-THC only inhibited locomotor activity significantly at a dose of 
100 mg/kg (p < 0.05). Once again, no significant main effect of diet was noted, F(1, 15) 
= 0.0995, p = 0.757, and the interaction between the dose of 9-THC and the type of diet 
consumed was not significant, F(4, 60) = 1.541, p = 0.202.
Hypothermia
Females. Female rats exhibited a significant main effect of 9-THC on body 
temperature each age point tested (Table 5). Doses of 9-THC that exceeded 30 mg/kg 
commonly induced significant hypothermia when compared to vehicle treatment (p < 
0.05). In contrast, neither a significant main effect of diet nor a significant interaction 
between type of diet and 9-THC on hypothermia were noted for at any age point. In 
female rats, the hypothermic effects of 9-THC were indistinguishable across the groups, 
regardless of the age point when tested.
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Figure 23.  Locomotor activity for male rats at PD68. Number of beams broken (mean 
+/- SEM) by male rats after treatment with 9-THC on postnatal day 68. A significant 
main effect of 9-THC on the number of beams broken was noted, No between-group 
differences in drug response were detected. Data points highlighted with a “#” are 
significantly different from the respective vehicle-treated conditions.
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Figure 24.  Locomotor activity for male rats at PD114. Number of beams broken 
(mean +/- SEM) by male rats after treatment with 9-THC on postnatal day 114. A 
significant main effect of 9-THC on the number of beams broken was noted, No 
between-group differences in drug response were detected. Data points highlighted 
with a “#” are significantly different from the respective vehicle-treated conditions.
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        Table 5
        Effects of 9-THC and type of diet on body temperature.
Main Effect of 9-THC Main Effect of Diet Interaction of 9-
THC and Diet
Females F-test
p-
value
F-test
p-
value
F-test
p-
value
PD30 F(4,64)=143.99 < 0.01 F(1,16)=1.42 > 0.05 F(4,64)=0.96 > 0.05
PD44 F(4,64)=98.35 < 0.01 F(1,16)=3.11 > 0.05 F(4,64)=1.77 > 0.05
PD68 F(4,64)=64.57 < 0.01 F(1,16)=0.22 > 0.05 F(4,64)=0.34 > 0.05
PD114 F(4,64)=115.72 < 0.01 F(1,16)=1.45 > 0.05 F(4,64)=0.41 > 0.05
Males F-test
p-
value
F-test
p-
value
F-test
p-
value
PD30 F(4,64)=109.08 < 0.01 F(1,16)=0.85 > 0.05 F(4,64)=0.52 > 0.05
PD37 F(4,60)=12.98 < 0.01 F(1,15)=0.14 > 0.05 F(4,60)=1.24 > 0.05
PD44 F(4,60)=8.35 < 0.01 F(1,15)=0.05 > 0.05 F(4,60)=1.82 > 0.05
PD61 F(4,60)=15.22 < 0.01 F(1,15)=0.12 > 0.05 F(4,60)=0.38 > 0.05
PD68 F(4,60)=26.53 < 0.01 F(1,15)=0.39 > 0.05 F(4,60)=0.95 > 0.05
PD114 F(4,60)=26.46 < 0.01 F(1,15)=0.02 > 0.05 F(4,60)=0.17 > 0.05
Males. For the male rats, there was also a significant main effect of 9-THC on 
body temperature each age point tested (Table 5). Again, doses of 9-THC that exceeded 
30 mg/kg induced significant hypothermia when compared to vehicle treatment (p < 
0.05). Like the female rats, neither a significant main effect of diet nor a significant 
interaction between type of diet and 9-THC on hypothermia were noted at any age point. 
Again like the female rats, the hypothermic effects of 9-THC in male rats were 
indistinguishable across the groups, regardless of the age point when tested. It is 
noteworthy, however, that both groups of male rats exhibited an attenuated hypothermic 
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response to 9-THC after the initial exposure and this pattern of diminished responses 
persisted through postnatal day 114.
Antinociception – Tail-flick
Females. Female rats exhibited a significant interaction between 9-THC and diet 
on latency to withdraw the tail from a radiant heat source, F(1, 16) = 9.075, p =0.008 
(Fig. 25A).  There was also a significant main effect of 9-THC on latency to withdraw 
the tail from the source, F(1, 16) = 386.570, p < 0.001). In contrast, no main effect of diet 
was detected, F(1, 16) = 0.0000684, p = 0.994. However, female rats maintained on a 
high-fat diet exhibited a smaller drug-related change in latency to withdraw the tail from 
the heat source (M = 3.636, SD = 0.603) than did the females maintained on the control 
diet (M = 4.963, SD = 1.159), t(16) = 3.050, p = 0.008 (Fig. 25B).
Males. For male rats, there was a significant main effect of 9-THC on latency to 
withdraw the tail from a radiant heat source, F(1, 15) = 427.949, p < 0.001 (Fig. 26A). A 
30 mg/kg dose of 9-THC significantly increased latency to withdraw the tail from the 
heat source than did treatment with vehicle (p < 0.05). There was not, however, a 
significant main effect of the type of diet on tail withdrawal latency F(1, 15) = 0.0547, p
= 0.818. Additionally, no significant interaction between the type of diet and the dose of 
9-THC was noted F(1, 15) = 0.418, p = 0.528. Unlike female rats, however, male rats 
maintained on a high-fat diet exhibited a drug-related change in latency to withdraw the 
tail from the heat source (M = 3.699, SD = 0.948) that was indistinguishable from the 
drug-related change in latency exhibited by the males maintained on the control diet (M = 
3.934, SD = 0.462), t(15) = 0.635, p = 0.535 (Fig. 26B).
70
VEH 30
1
2
3
4
5
6
7
8
9
Females
Control Diet
High-fat Diet
9-THC (mg/kg)
L
at
en
cy
 t
o
 W
it
h
d
ra
w
 T
ai
l 
(s
ec
s)
Control Diet High-fat Diet
1
2
3
4
5
6
7
Control Diet
High-fat Diet
Females
**
C
h
an
g
e 
in
 L
at
en
cy
 t
o
 W
it
h
d
ra
w
 T
ai
l 
(s
ec
s)
A B
Figure 25.  Antinociception in female rats. Changes in tail-flick latency produced by 
treatment with 9-THC. Female rats demonstrated a significant interaction between 
diet and 9-THC on tail-flick latencies (Fig 25A). A main effect of 9-THC on tail-
flick latency was also noted in female rats. Female rats maintained on a high-fat diet 
also exhibited significantly smaller changes in tail-flick latencies after treatment with a 
30 mg/kg dose of 9-THC than female rats maintained on the control diet (Fig. 25B; 
“**” indicates p < 0.01).
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Figure 26.  Antinociception in male rats. Changes in tail-flick latency produced by 
treatment with 9-THC. Male rats demonstrated a significant main effect of 9-THC 
on tail-flick latencies (Fig 26A). Unlike female rats, however, male rats did not exhibit 
an interaction between diet and 9-THC on tail-flick latencies. Additionally, the 
changes in tail-flick latencies induced by treatment with a 30 mg/kg dose of 9-THC 
were indistinguishable across the groups (Fig. 26B).
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Food-intake
Females. During the first hour of a 3-hour feeding trial, female rats exhibited a 
significant main effect of 9-THC on food intake, F(5, 80) =  6.855, p < 0.001 (Fig. 27). 
Food intake increased significantly when rats were treated with 1 mg/kg, 3 mg/kg and 10 
mg/kg doses of 9-THC when compared with vehicle. Analysis also revealed a 
significant main effect of diet on food intake, F(1, 16) = 8.686, p = 0.009, with female 
rats maintained on a high-fat diet consuming significantly more food during the feeding 
trial than the female rats maintained on the control diet. Despite this, no interaction 
between 9-THC and diet on food intake was detected, F(5, 80) = 0.809, p = 0.547.  
Over the course of the full 3-hour feeding trial, female rats exhibited a significant 
interaction of 9-THC and diet on food intake, F(5, 79) =  7.350, p < 0.001 (Fig. 28). 
Analysis also revealed significant main effects of 9-THC dose, F(5, 79) = 9.915, p < 
0.001, and of diet on food intake, F(1, 16) = 8.874, p = 0.009. The female rats maintained 
on a high-fat diet ate significantly more than the female rats maintained on the control 
diet when treated with 10 mg/kg and 30 mg /kg doses of 9-THC (p < 0.05 for both 
measures). Conversely, female rats maintained on the control diet ate significantly more 
than female rats maintained on a high-fat diet when treated with a 1 mg/kg dose of 9-
THC (p < 0.05).
In the same 3-hour experiment, female rats maintained on the control diet ate 
significantly more when treated with a 1 mg/kg dose of 9-THC than with treated with 
vehicle, p < 0.05. Female rats maintained on the high-fat diet, however, ate significantly 
more when treated with 3 mg/kg and 10 mg/kg doses of 9-THC doses than when treated 
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Figure 27.  Relative food-intake over the first hour of a 3-hour feeding trial in female 
rats. A significant main effect of 9-THC on food intake was noted. Neither an 
interaction between diet and 9-THC on food intake nor a main effect of diet were 
detected. Compared to vehicle conditions, food intake was stimulated 1 mg/kg – 10 
mg/kg in female rats maintained on a high-fat diet. Female rats maintained on the 
control diet ate significantly more when treated with a 1 mg/kg dose of 9-THC than 
when treated with vehicle. Data points highlighted with “#” are significantly different 
from the respective vehicle-treated conditions. 
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Figure 28.  Relative food-intake over the course of a 3-hour feeding trial in female 
rats. A significant interaction between diet and 9-THC on food intake was noted. 
Additionally, a main effect of dose and a main effect of diet were detected. Compared 
to vehicle conditions, food intake was stimulated at 3 mg/kg and 10 mg/kg doses of 
9-THC in female rats maintained on a high-fat diet. Female rats maintained on the 
control diet ate significantly more when treated with a 1 mg/kg dose of 9-THC than 
when treated with vehicle. Data points highlighted with “#” are significantly different 
from the respective vehicle-treated conditions. Data points highlighted with an asterisk 
are significantly different from the control diet group (“*” indicates p < 0.05; “***” 
indicates p < 0.001).
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with vehicle (p < 0.05 for both measures). Both the smallest dose (e.g., 0.3 mg/kg) and 
the largest dose of 9-THC (e.g., 30 mg/kg) failed to produce changes in food intake in 
either group compared to vehicle.
Males. Over the course of a 1-hour feeding trial, the male rats exhibited a 
significant interaction between diet and 9-THC on food intake, F(4,60) = 3.693, p = 
0.009 (Fig. 29). Analysis also revealed significant main effects of 9-THC, F(4, 60) = 
83.927, p < 0.001, and diet on food intake, F(1, 15) = 10.200, p = 0.006. Male rats 
maintained on a high-fat diet ate significantly more than rats maintained on the control 
diet when treated with vehicle and with a 3 mg/kg dose 9-THC (p < 0.05 for both 
measures).  
Context-specific tolerance
In a test of context-specific tolerance, male rats exhibited a significant interaction 
between the drug exposure environment and 9-THC on hypothermia, F(4, 24) = 3.450, p
= 0.023. The male rats used in these experiments exhibited a main effect of 9-THC on 
hypothermia when first exposed to the drug (PD30; Fig. 30A). Despite this, the rats that 
were treated with 9-THC in two distinct environments (e.g., a behavioral pharmacology 
lab and the vivarium) seven days apart (PD30 and PD37) exhibited significantly less 
hypothermia on the second exposure than male rats that were treated with 9-THC in the 
same environment at those same age points, p < 0.05 (Fig. 30B). At a 100 mg/kg dose, 
the group of males that been exposed to 9-THC in two discrete locations exhibited less 
hypothermia than the group of males that had been exposed to 9-THC in the same 
environment twice (p < 0.05). The mean baseline body temperatures of the two groups 
76
Males - 1-hr Food Intake
VEH
0.00
0.01
0.02
0.03 High-fat Diet
Control Diet
0.3 1 3 10
*
***
#
#
#
#
9-THC (mg/kg)
E
n
e
rg
y 
C
o
n
su
m
p
ti
on
 (
kc
al
/g
 b
o
dy
w
e
ig
ht
)
Figure 29.  Relative food-intake over the course of a 1-hour feeding trial in male rats. 
A significant interaction between diet and 9-THC on food intake was noted. 
Additionally, a main effect of dose and a main effect of diet were detected. Under 
vehicle conditions, male rats maintained on a high-fat diet ate significantly more than 
male rats maintained on the control diet. Compared to vehicle conditions, food intake 
was inhibited at 3 mg/kg and 10 mg/kg doses of 9-THC in both groups of male rats. 
Data points highlighted with “#” are significantly different from the respective 
vehicle-treated conditions. Data points highlighted with an asterisk are significantly 
different from the control diet group (“*” indicates p < 0.05; “***” indicates p < 0.001).
were indistinguishable on PD30 (Lab/Lab group = 37.4oC, Lab/Vivarium group = 
37.5oC) and on PD37 (Lab/Lab group = 37.6oC, Lab/Vivarium group = 37.3oC).
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Figure 30.  Context-specific tolerance to the hypothermic properties of 9-THC. Upon 
initial exposure (PD30; Fig. 30A), a significant main effect of 9-THC on 
hypothermia was evident in both groups. The initial exposure to 9-THC took place in 
a behavioral pharmacology lab for both groups. On the subsequent exposure (PD37; 
Fig. 30B), a significant main effect of 9-THC on hypothermia was not detectable. 
There was, however, a significant interaction between the location of the second 
exposure and 9-THC on hypothermia. Data points highlighted with an asterisk are 
significantly different from the control diet group (“*” p < 0.05).
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Discussion
Females
The most striking finding from these experiments is that, in female (but not male) 
rats, consumption of a high-fat diet throughout adolescence resulted in reduced sensitivity 
to the psychomotor effects of 9-THC. Within two weeks of the female rats being placed 
on the high-fat diet, a trend suggestive of cross-tolerance to the psychomotor effects of 
9-THC began to develop.
If present, this cross-tolerance may be the result of chronically elevated 
endocannabinoid signaling produced by the inhibition of anandamide hydrolysis. The 
type and quantity of polyunsaturated fatty acids in the diet can directly influence 
endocannabinoid levels (Berger et al., 2001; Watanabe et al., 2003). Diets rich in omega-
6-polyunsaturated fatty acids may increase endocannabinoid levels by providing 
additional substrate for FAAH (Matias et al., 2006).  It may be possible to inhibit the 
activity of by providing additional substrate because FAAH hydrolyzes the amide bond 
of several common amines formed from long-chain fatty acids, including anandamide
(Schmid et al., 1985; Ueda et al., 1995).  
By the time of the final assessment on postnatal day 114, 9-THC produced 
smaller increases in the amount of time on the bar apparatus and did not inhibit 
locomotion in females maintained on the high-fat diet compared to the females 
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maintained on the control diet. Further, female rats maintained on this diet were less 
sensitive to increased food intake caused by 9-THC. These changes in drug response are 
strikingly similar to changes seen in rats that are tolerant to 9-THC (Fan et al., 1994). 
The impression that female rats maintained on a high-fat diet became cross-
tolerant to the psychomotor effects of 9-THC was reinforced by other observations made 
during these trials. Female rats maintained on a high-fat diet appeared to be less sedated 
by moderate and high doses of 9-THC (i.e., above 10 mg/kg) than female rats 
maintained on a control diet.
Other non-systematic observations made over the course of these experiments 
suggest that female rats maintained on a high-fat diet found high doses of 9-THC (e.g., 
100 mg/kg) to be less aversive than female rats maintained on the control diet. Doses of 
some drugs (i.e., naloxone, lithium chloride) that produce conditioned place aversion are 
associated with an increase in ultrasonic vocalizations in the 20kHz frequency range as 
compared to similar vocalizations made by vehicle-treated animals (Burgdorf et al., 
2001). Tones in the 20kHz range are near the high-end of the audible frequency range for 
humans (Jauchem and Cook, 2007). When treated with a 100 mg/kg dose of 9-THC, 
female rats maintained on the control diet commonly emitted sustained, high-pitched 
vocalizations in response to being handled. In contrast, female rats maintained on a high-
fat diet rarely emitted vocal responses after being touched. 
While suggestive of cross-tolerance to cannabinoids, however, the phenotype 
resulting from this dietary regimen is distinct from that observed in cannabinoid tolerant 
animals. For example, the female rats maintained on this diet also commonly exhibited a 
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repetitive, stereotyped series head movements when treated with high doses of 9-THC, 
an effect that does not occur in cannabinoid-tolerant rats. It is unclear whether these head 
movements are a unique consequence of cannabinoid exposure after sustained 
consumption of a high-fat diet or if they are simple exaggerations of other common 
movements.
Notably, other cannabinoid-mediated effects, such as hypothermia and 
antinociception were unaffected or minimally affected.  Importantly, it has been 
demonstrated that cannabinoid tolerance can develop in an asymmetric fashion. For 
instance, after treatment with the CB1 agonist CP55, 940 for 4 consecutive days, rats 
developed tolerance to the antinociceptive effects of the drug while the effect on operant 
responding for food remained unchanged (DeVry et al., 2004). In this same study, a non-
significant trend toward tolerance to the hypothermic effect of CP55, 940 was noted.  In 
addition, these data suggest that the observed changes in sensitivity to the psychomotor 
effects of 9-THC in female rats maintained on a high-fat diet is probably not attributable 
to differential metabolism or altered bioavailability of 9-THC.
It could be also reasoned that, because 9-THC is highly lipophilic and passes into 
fat cells easily, changes in sensitivity to the psychomotor effects of 9-THC could be 
attributable to increased adiposity and a concomitant reduction in drug bioavailability. 
Once again, the lack of a main effect of diet on the hypothermic properties of 9-THC 
argues against this conclusion.  
Another interesting finding from these studies is related to observed changes in 
food intake after treatment with 9-THC that occurred in female rats. The graphs of food 
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intake after treatment with 9-THC depict a classical rightward shift in the dose-response 
curve. As such, it appears that the female rats maintained on a high-fat diet were tolerant 
to 9-THC-induced changes in food intake. The feeding behavior exhibited by the female 
rats maintained on the control diet is consistent with 9-THC-induced changes reported 
by other investigators (Williams et al., 1998). However, 9-THC continued to stimulate 
food intake in the female rats that were maintained on a high-fat diet at doses that were 
inactive or reduced food intake in other studies (Koch and Matthews, 2001).
It is important to point out a potential confound inherent to the food-intake 
studies. Changes in food intake after treatment with 9-THC were measured using the 
food that was normally consumed by each group. In other words, the female rats 
maintained on a high-fat diet ate high-fat chow during the feeding trials. Similarly, 
female rats maintained on the control diet ate standard rodent chow during their feeding 
trials. Diets were not changed during the feeding trials because of potential inter-group 
differences in the hedonic value of food or in the degree of neophobia. Though measuring 
food intake with a common diet would have eliminated one condition that varied 
systematically with drug treatment, it would have added at least one more.
It has been demonstrated that CP-55940, a potent CB1 agonist, differentially 
enhances the reinforcing efficacy of corn oil as compared to vehicle (Ward and Dykstra, 
2005), but it is not clear whether the high-fat diet used in these studies would be similarly 
appealing after treatment with cannabinoids. It is possible that the observed inter-group 
differences in food-intake are related to a differential influence of 9-THC on the intake 
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of high-fat foods. An examination of the reinforcing efficacy of the high-fat diet used in 
these studies provides one possible future direction for this project.
Males
In contrast, male rats maintained on a high-fat diet across the same developmental 
interval were only affected to a moderate degree. Male rats maintained on a high-fat diet 
spent more time on the bar apparatus when treated with 9-THC than male rats 
maintained on the control diet, but this difference only appeared after the high-fat diet 
had been consumed for 12 weeks and there were no overt differences in their level of 
sedation at higher doses. Although this observation was not obtained systematically, it 
stands in contrast to similar observations made during the trials with the female rats. 
Additionally, male rats maintained on the control diet ate significantly less than male rats 
maintained on a high-fat diet when treated with a 3 mg/kg dose of 9-THC, though 
baseline differences in food intake between the groups complicate the interpretation of 
these data. Measures of gross locomotion, hypothermia and antinociception did not reveal 
any differences between the male rats maintained on a high-fat diet and male rats 
maintained on the control diet.
Unlike female rats, the male rats maintained on a high-fat diet never differed 
significantly from the male rats maintained on the control diet in terms of the number of 
beams broken. Although a dose-dependent relationship between 9-THC dose and the 
number of beams broken persisted through postnatal day 114, locomotion was only 
significantly inhibited by large doses of 9-THC (e.g., 100 mg/kg) at that age. The 
observation that both groups of male rats were less sensitive to the locomotor inhibition 
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caused by 9-THC is intriguing, if not a bit puzzling. It is unlikely that these data can be 
explained in terms of pharmacokinetic tolerance because these rats had not been treated 
with 9-THC in 45 days. Pharmacokinetic explanations are also inconsistent with the 
robust dose-dependent relationship between 9-THC and the amount of time spent on the 
bar apparatus was apparent at postnatal day 114. This leaves open the possibility of 
context-specific tolerance to the locomotor effects of 9-THC. Previous work has 
demonstrated that behavioral tolerance to the locomotor effects of cannabinoids can be 
produced after repeatedly pairing a cannabinoid agonist (HU210) with a locomotor 
chamber (Hill et al., 2004).  It is also possible that there are sex differences in the rate at 
which these rats became habituated to the locomotor chamber (Bolivar et al., 2000). 
Another intriguing finding from these experiments is the rapidity and degree to 
which young male rats developed tolerance to the hypothermic effects of 9-THC. At 
postnatal day 30, a 100 mg/kg dose of 9-THC administered under a cumulative dosing 
regimen reduced body temperatures by about 2.1o Celsius.  When the male rats were 
tested again at postnatal day 37, 9-THC proved to be less efficacious at reducing body 
temperature in both groups. Although a dose-dependent relationship between 9-THC 
and hypothermia continued through postnatal day 114, the maximum degree of 
hypothermia observed at any subsequent age point was about 1o Celsius. This trend held 
true for both groups. Neither a main effect of diet nor an interaction of diet and dose of 
9-THC on hypothermia were observed in male rats at any age.
When a separate group of young male rats were exposed to a cumulative dosing 
protocol identical to the one used in these experiments, profound tolerance to the 
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hypothermic effects of 9-THC developed after a single session. The tolerance that 
developed after the cumulative dosing session on postnatal day 30 was still evident on 
postnatal day 37 and was robust enough to eliminate the hypothermic response to even 
large doses of 9-THC (100 mg/kg).
Even though there was no significant main effect of the dose 9-THC on 
hypothermia at postnatal day 37, there was a significant interaction between the 
environment where the second test was conducted and the hypothermic effects of 9-
THC. In a most unusual twist, however, hypothermic responses to 9-THC were least 
evident in the environment that had never been paired 9-THC. At the very least, these 
results suggest that context-specific tolerance plays a very small part in the diminished 
hypothermic response that appeared after first cumulative dosing session.
Also unlike in the female rats, sustained consumption of a high-fat did not 
significantly alter the antinociceptive properties of 9-THC in male rats. Under both 
vehicle conditions and drug conditions, tail withdrawal latencies were virtually identical 
for both groups. Likewise, both groups of male rats exhibited similar drug-related 
changes in the latency to withdraw the tail from the noxious stimuli caused by the radiant 
heat lamp.
Possible Mechanisms of Tolerance
While it cannot yet be concluded that the diet-related changes in sensitivity to the 
effects of 9-THC observed in these studies involve receptor-level changes, there is no 
evidence that observed differences in sensitivity to 9-THC are attributable to diet-related 
differences in pharmacokinetics. The data, however, are generally consistent with the 
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region-specific changes in CB1 receptor density reported in elsewhere (Harrold, et al., 
2002; Hayakawa, et al., 2007). In these studies, CB1 receptor expression appeared to 
decline significantly in the striatum and nucleus accumbens while remaining essentially 
unaltered in the hypothalamus after sustained consumption of a high-fat diet. 
It would be expected that diminished CB1 receptor expression in the striatum 
would result in reduced sensitivity to the psychomotor effects of 9-THC. Similarly, it 
would be expected that diminished CB1 receptor expression in the nucleus accumbens 
would attenuate the augmentation of the hedonic value of food caused by 9-THC. In 
contrast, unaltered CB1 receptor expression in the hypothalamus would likely result in an 
unaltered hypothermic response to 9-THC. Each of these expectations is consistent with 
the data derived from these experiments.
Sex-differences in Drug Response
Despite the evidence that a high-fat diet alters sensitivity to 9-THC-induced 
changes in food intake and, to a lesser degree, the antinociceptive properties of 9-THC, 
these studies do not allow for a direct examination of sex differences because of differing 
treatment histories for each sex. Male rats endured prolonged periods of inactivity (e.g., 
3-9 months) between testing in the triad of measures that compose the experimental core 
of this project (e.g., hypothermia, gross locomotor activity, time on bar apparatus) and the 
beginning of the feeding trials and the tail withdrawal tests. The female rats, on the other 
hand, were moved from the triad of measures to the feeding trials and tail withdrawal 
tests as rapidly as practical. Accordingly, the food intake data and the measures of 
antinociception were conducted at different age points for each sex.
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It is well-known that nutritional status can affect the menstrual cycle of humans 
(Frisch and McArthur, 1974). There is evidence of a positive correlation between the 
consumption dietary fats and plasma estrogen levels during some phases of the human 
menstrual cycle (Kaneda et al., 1997). Despite this, high dietary intake of polyunsaturated 
fats is not associated with changes in menstrual cycle length (Nagata, Oba and Shimizu, 
2006).  
Given the evidence derived from humans, it is at least possible that high-fat diets 
alter estrogen levels rodents. If present, such alterations could be important in the current 
context because there is some evidence that CB1 receptor expression in the anterior 
pituitary gland fluctuates during the course of the rodent estrous cycle and is related to 
circulating levels of estrogen (Gonzalez et al., 2000). It is not clear, however, whether a 
similar relationship exists in other brain areas. While it is possible that high-fat diets 
modulate CB1 receptor expression in the brain by altering circulating estrogen levels, 
there is scant evidence to support such a conclusion. 
Recent evidence from experiments with ovariectomized mice, however, suggests 
that progesterone may be an important modulator of cannabinoid-induced catalepsy 
(Kalbasi Anaraki et al., 2008). Cannabinoid-induced catalepsy was unaltered when 
ovariectomized mice were treated with estrogen, but treatment with progesterone 
potentiated the cataleptogenic properties of cannabinoids. It is important to remember, 
however, that progesterone levels may decline in female rats that consume high levels of 
omega-6-polyunsaturated fats (Trujillo and Broughton, 1995). The corn oil used as a 
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source of dietary fat in this study is rich in omega-6-polyunsaturated fats (U.S. 
Department of Agriculture, Agricultural Research Service, 2005).
While there appears to be a relationship between the type of diet used in these 
experiments and low levels of progesterone levels in rats, there is no direct evidence that 
low levels of progesterone would attenuate catalepsy-like behavior induced by 9-THC. 
The relationship between high-fat diets, progesterone levels and the cataleptogenic 
properties 9-THC is one possible future direction for this project.
The experiments with the male rats were conducted in the summer and 
experiments with the female rats were conducted nearly fifteen months later in the late 
fall and early winter. As a consequence, potential seasonal differences in the data make a 
direct comparison of sex-differences in diet-related changes in sensitivity to 9-THC 
inadvisable. Despite this, there was an obvious disparity in the diet-related changes in the 
sensitivity to 9-THC that were observed within each sex. In male rats, there were very 
few diet-related changes in the psychomotor effects of 9-THC, regardless of the diet 
consumed. As mentioned previously, however, female rats had been maintained on high-
fat diet for at least thirty-eight days were much less sensitive to the psychomotor effects 
of 9-THC than female rats maintained on the control diet. 
The results of these experiments raise questions regarding the relationship 
between sustained consumption of a high-fat diet and the developing brain. It is not clear 
whether diet-related differences in sensitivity to 9-THC are caused by the consumption 
of high-fat diets during a vulnerable period of brain development, or whether rats that are 
placed on high-fat diets in adulthood would eventually exhibit a similar type of 
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desensitization. These are compelling questions and they may be related to an important 
public health issue, but they cannot be answered without further experimentation.
Despite these limitations, the apparent sex differences in the effect of a high-fat 
diet on sensitivity to some of the pharmacological effects of 9-THC are intriguing. As of 
yet, the degree to which sex hormones influence these differences is unclear. Clearly, 
parallel trials should be conducted with groups of overiectomized females and castrated 
males maintained on each of the diets. It is also not yet clear whether the diet-related 
differences in sensitivity to 9-THC involve differences in CB1 receptor sensitivity. 
Accordingly, CB1 receptor function should be studied in drug-naïve rats of both sexes 
that have been maintained on each of the diets.
The degree to which the various phases of the estrous cycle influence sensitivity 
to 9-THC in rodents is of fundamental importance, but there is a paucity of research in 
this area. The female rats used in these studies were housed separately in cages that were 
under positive airflow. This housing arrangement and the positive airflow environment of 
the home cages should have impaired estrous synchrony in these rats (Schank and 
McClintock, 1997). 
The experiments detailed here were designed as part of a developmental study and 
employ methodologies that are distinct from those used in studies designed to explore 
sex-differences. While the phase of the estrous cycle was not considered during these 
experiments, it is improbable that the female rats maintained on a high-fat diet randomly 
expressed synchronized estrous cycles while being uniformly out-of-phase with the 
female rats maintained on the control diet. Female rats have an estrous cycle that lasts 
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between 4 and 5 days (Butterstein et al., 1997). Assuming a mean estrous cycle duration 
of 4.5 days, the probability of nine rats randomly expressing a synchronized estrous cycle 
while nine other rats were randomly asynchronous is (0.2228 X 0.7789) or 6.19 X 10-7.
In conclusion, the data derived from these experiments suggest that, in female 
rats, sustained consumption of a high-fat diet throughout adolescence and into adulthood 
significantly reduces sensitivity to the psychomotor effects of 9-THC when compared to 
female rats maintained on the control diet. Further, female rats maintained on the high-fat 
diet were less sensitive to the changes in food intake caused by 9-THC than were female 
rats maintained on the control diet. In contrast, relatively few differences in the 
sensitivity to 9-THC were noted in male rats maintained under the same dietary 
conditions throughout the same developmental period.
These findings raise questions regarding possible sex-differences in the 
pharmacokinetics of 9-THC, as well as the relationship between dietary fats, sex 
hormones and 9-THC. Further, it is not clear whether similar results would be seen in 
female rats that began eating a high-fat in adulthood. The mechanism(s) by which high-
fat diets differentially alter sensitivity 9-THC across the sexes has yet to be elucidated 
and the possibility of diet-related changes in endocannabinoid signaling must considered 
in the light of these results. All of these topics represent possible future directions for 
these studies.
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